University of Nebraska Medical Center

DigitalCommons@UNMC
Theses & Dissertations

Graduate Studies

Summer 8-19-2016

Psychological Aspects of Head and Neck Cancer
Katherine Rieke
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/etd
Part of the Epidemiology Commons

Recommended Citation
Rieke, Katherine, "Psychological Aspects of Head and Neck Cancer" (2016). Theses & Dissertations. 208.
https://digitalcommons.unmc.edu/etd/208

This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

i
PSYCHOLOGICAL ASPECTS OF HEAD AND NECK CANCER
by
Katherine R. Rieke, MPH MA

A DISSERTATION

Presented to the Faculty of
the University of Nebraska Graduate College
in Partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy

Epidemiology Graduate Program

Under the Supervision of Shinobu Watanabe-Galloway, PhD

University of Nebraska Medical Center
Omaha, Nebraska
June, 2016

Supervisory Committee:
Julia Houfek, PhD RN; William M. Lydiatt, MD; Kendra K. Schmid, PhD

ii

ACKNOWLEDGMENTS
I would like to acknowledge the many people who have made this dissertation possible. First, I
would like to thank my committee for all their effort and constant support on these projects.
A very special thanks goes to Eugene Boilesen, without whom my work on these projects would
not be possible.
I would like to thank the Department of Otolaryngology – Head and Neck Surgery at the
Nebraska Medical Center for all they have done for me over the last few years and for helping me
better understand head and neck cancer and those fighting it.
To Mary Morris and Jean Palmer for all they do.
Thanks also to Dr. Amr Soliman, Dr. Robert Chamberlain, and Melanie Wells of the Cancer
Epidemiology Education in Special Populations Program of the University of Nebraska for their
support on this project.
Finally, I would like to thank my family and friends for their continuous understanding, sacrifice,
and encouragement.

iii

FUNDING AND OTHER ACKNOWLEDGEMENTS
Katherine Rieke was supported by the Cancer Epidemiology Education in Special Populations
Program of the University of Nebraska (R25 CA112383). The content is solely the responsibility
of the authors and does not necessarily represent the official views of National Cancer Institute or
the National Institutes of Health.

This study used the linked Surveillance Epidemiology and End Results -Medicare database. The
interpretation and reporting of these data are the sole responsibility of the authors. The authors
acknowledge the efforts of the National Cancer Institute; the Office of Research, Development
and Information, Centers for Medicare and Medicaid Services; Information Management
Services, Inc.; and the Surveillance, Epidemiology, and End Results Program tumor registries in
the creation of the Surveillance, Epidemiology, and End Results-Medicare database.
The collection of cancer incidence data used in this study was supported by the California
Department of Public Health as part of the statewide cancer reporting program mandated by
California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance,
Epidemiology and End Results Program under contract HHSN261201000140C awarded to the
Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the
University of Southern California, and contract HHSN261201000034C awarded to the Public
Health Institute; and the Centers for Disease Control and Prevention's National Program of
Cancer Registries, under agreement # U58DP003862-01 awarded to the California Department of
Public Health. The ideas and opinions expressed herein are those of the author(s) and
endorsement by the State of California Department of Public Health, the National Cancer
Institute, and the Centers for Disease Control and Prevention or their Contractors and
Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the
National Cancer Institute; the Office of Research, Development and Information, Centers for
Medicare and Medicaid Services; Information Management Services, Inc.; and the Surveillance,
Epidemiology, and End Results Program tumor registries in the creation of the Surveillance,
Epidemiology, and End Results-Medicare database.

iv

TABLE OF CONTENTS
LIST OF TABLES ........................................................................................................... viii
LIST OF FIGURES ........................................................................................................... ix
LIST OF ABBREVIATIONS ............................................................................................. x

ABSTRACT .................................................................................................................... xi

CHAPTER 1: OVERVIEW OF HEAD AND NECK CANCER
What is Head and Neck Cancer? ....................................................................................... 1
Oral cavity and oropharyngeal cancers .................................................................. 1
Nasopharyngeal cancer. ......................................................................................... 2
Laryngeal and hypopharyngeal cancer .................................................................. 2
Epidemiology of Head and Neck Cancer ............................................................................ 3
Risk Factors for Head and Neck Cancer ............................................................................. 4
Tobacco and alcohol use. ....................................................................................... 4
Infections. .............................................................................................................. 5
Age, gender, and race. ........................................................................................... 5
Other risk factors ................................................................................................... 6
Diagnosis of Head and Neck Cancer .................................................................................. 7
Staging and Treatment of Head and Neck Cancer .............................................................. 7
DEPRESSION IN HEAD AND NECK CANCER ......................................................... 9
Cancer and Depression ....................................................................................................... 9
Depression Preceding Cancer ........................................................................................... 10
Depression and Cancer Diagnosis .................................................................................... 11
Radiation Treatment and Depression ................................................................................ 12
Depression and Survival Outcomes among Head and Neck Patients ............................... 13

v
Limitations of Previous Research ..................................................................................... 13
SEER-Medicare Linked Database as a Unique Source of Depression Research
.......................................................................................................................................... 14
Specific Aims .................................................................................................................... 16

CHAPTER II: CONCEPTUAL MODEL DEVELOPMENT TO UNDERSTAND THE
PATHWAY TO DEPRESSION AMONG HEAD AND NECK CANCER PATIENTS
Abstract ............................................................................................................................. 17
Background ....................................................................................................................... 17
Methods ............................................................................................................................ 19
Results............................................................................................................................... 20
Previous models ................................................................................................... 21
Factors influencing preexisting depression .......................................................... 21
Factors influencing depression after cancer diagnosis ......................................... 22
Factors influencing head and neck cancer outcomes ........................................... 24
Discussion ......................................................................................................................... 24

CHAPTER III: POPULATION-BASED RETROSPECTIVE STUDY TO INVESTIGATE
PREEXISTING AND NEW DEPRESSION DIAGNOSIS AMONG HEAD AND NECK
CANCER PATIENTS
Abstract ............................................................................................................................. 28
Introduction ....................................................................................................................... 28
Materials and Methods ...................................................................................................... 30
Study sample ........................................................................................................ 30
Depression identification and statistical analysis................................................. 31
Results............................................................................................................................... 32
Prevalence and incidence of depression .............................................................. 32
Multivariable analysis .......................................................................................... 33

vi
Discussion ......................................................................................................................... 34
Conclusions ....................................................................................................................... 37

CHAPTER IV: SURVIVAL AND DEPRESSION IN HEAD AND NECK CANCER
PATIENTS
Abstract ............................................................................................................................. 42
Introduction ....................................................................................................................... 43
Materials and Methods ...................................................................................................... 44
Statistical analysis ................................................................................................ 45
Results............................................................................................................................... 46
Bivariate analysis ................................................................................................. 46
Multivariable analysis .......................................................................................... 47
Discussion ......................................................................................................................... 48
Conclusions ....................................................................................................................... 50

CHAPTER V: RADIATION SIDE-EFFECTS AND DEPRESSION IN INHEAD AND
NECK CANCER PATIENTS
Abstract ............................................................................................................................. 54
Introduction ....................................................................................................................... 55
Methods ............................................................................................................................ 56
Results............................................................................................................................... 57
Bivariate analysis ................................................................................................. 57
Multivariable analysis .......................................................................................... 58
Discussion ......................................................................................................................... 58
Conclusions ....................................................................................................................... 61

CHAPTER VI: DISCUSSION AND CONCLUSIONS

vii
Summary of Current Research .......................................................................................... 65
Implications of Current Research ..................................................................................... 67
Suggested Future Research ............................................................................................... 69
Limitations ........................................................................................................................ 71
Conclusions ....................................................................................................................... 72

REFERENCES ................................................................................................................. 73
APPENDIX ...................................................................................................................... 95

viii

LIST OF TABLES
Factors influencing depression development in HNC patients ......................................... 26
Demographics by pre-HNC depression diagnosis ............................................................ 38
Demographics by post-HNC depression diagnosis ........................................................... 39
Multivariable logistic regression results for diagnosis of depression two years before HNC
.......................................................................................................................................... 40
Multivariable logistic regression results for diagnosis of depression one year after HNC
.......................................................................................................................................... 41
Profile of the study sample by depression status .............................................................. 51
Multivariable results for cancer-specific mortality ........................................................... 52
Multivariable results for all-cause mortality ..................................................................... 53
Profile of the study sample by depression status .............................................................. 62
Potential radiation side-effects in the study sample by depression status ......................... 63
Multivariable analysis of depression diagnosis in HNC patients...................................... 64

ix
LIST OF FIGURES
Proposed conceptual model of the pathway to depression among head and neck cancer (HNC)
patients .............................................................................................................................. 27

x

LIST OF ABBREVIATIONS
HNC

Head and neck cancer

US

United States

NPC

Nasopharyngeal Carcinoma

EBV

Epstein Barr Virus

HPV

Human Papillomavirus

PAF

Population Attributable Fraction

NCDB

National Cancer Database

CT

Computed Tomography

PET

Positron Emission Tomography

AJCC

The American Joint Commission on Cancer

PTSD

Posttraumatic Stress Disorder

DNA

Deoxyribonucleic Acid

SEER

Surveillance, Epidemiology, and End Results

ICD-O3

International Classification of Disease for Oncology, Version 3

ICD-9-CM

International Classification of Diseases, Ninth Revision, Clinical
Modification

CCI

Charlson Comorbidity Index

HMO

Health Maintenance Organization

OR

Odds Ratio

95% CI

95% Confidence Interval

HR

Hazard Ratio

PHQ

Patient Health Questionnaire

xi
ABSTRACT
Patients with head and neck cancer may be at increased risk for depression diagnosis when
compared to other cancer sites, both before and after their cancer diagnosis. Behavioral risk
factors for head and neck cancers, including tobacco and alcohol use, may be indicative of
depression before cancer diagnosis. Further, head and neck cancers and their treatments can cause
serious morbidity among patients, including physical disfigurement and loss of function.
Additionally, these cancers are often accompanied by social stigma, personal shame, and guilt.
While there is a significant body of research examining depression in this cancer population,
there are still several gaps in the existing literature.
This dissertation explores the relationship between depression and head and neck cancer.
Utilizing SEER-Medicare data, this research examines the rates of depression in the elderly adult
head and neck cancer population, the influence that depression has on stage and survival, and the
associations between radiation treatment side-effects and depression diagnosis. The results of the
studies included in this dissertation may assist in guiding interventions for depression prevention
and management in this population, and in improving cancer outcomes and quality of life for
head and neck cancer patients.
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CHAPTER I
OVERVIEW OF HEAD AND NECK CANCER

What Is Head and Neck Cancer?
Head and neck cancers (HNC) are malignancies of the upper aerodigestive tract and
include areas of the body such as oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx
(1; 2). According to a recent GLOBOCAN report by the International Agency for Research on
Cancer, in 2008 HNC was the seventh most common cancer in the world (1; 3). Though often
grouped together, HNCs are a relatively heterogeneous group of cancers, affecting different parts
of the body and physical function.
HNCs can have significant effects on morbidity and mortality of patients, as well as their
quality of life and well-being. In this dissertation, we will first examine this disease and its
treatments in order to better understand how HNC can affect those diagnosed. HNCs can be
grouped into sub-categories based on location in the body as well as specific cancer type. In the
subsequent sections, we will describe the following groups of HNCs in more detail: Oral cavity
and oropharyngeal cancers, nasopharyngeal cancers, and laryngeal and hypopharyngeal cancers.

Oral cavity and oropharyngeal cancers. The oral cavity includes the mucosal lining of
the lips, buccal mucosa, retromolar trigone, alveolar ridges, the anterior tongue, floor of the
mouth, and the hard palate (4). The oropharynx includes the posterior third of the tongue, the soft
palate and uvula, tonsils, and the upper part of the posterior pharyngeal wall (4). The oral cavity
and oropharynx help in breathing, talking, eating, chewing, and swallowing, while salivary glands
produce saliva that aids in food digestion (5).
Different cancers can develop from the various cells in the oral cavity and oropharynx.
Squamous cell carcinomas make up around 90% of cancer in these areas of the body (4).
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However, other types, including lymphomas, adenocarcinoma of the salivary glands, and
malignant melanomas can also occur (4). Based on national estimates, approximately 1.1% of
males and females in the United States (US) will receive a diagnosis of oral or pharynx cancer
during their lifetime (6). In 2015 alone, it is estimated that there were over 45, 000 new cases of
oral cavity and pharynx cancer nationally (7).

Nasopharyngeal cancer. The nasopharynx is the portion of the pharynx located behind
the nasal cavities located behind the nose, just above the oropharynx (8). The nasopharynx serves
as a passage for air into the body (9).
Nasopharyngeal carcinomas (NPC) are the most common malignancies of the
nasopharynx, and arise in the epithelial cells and include squamous cell carcinomas, nonkeratinizing carcinomas, and undifferentiated carcinomas (10; 11). Other types of cancers that can
occur in the nasopharynx include lymphomas and adenocarcinoma and adenoid cystic carcinomas
(12).
NPC is much more commonly found in certain parts of Asia and Africa, and tends to
afflict men more than women (10). In the US, NPC is relatively uncommon, representing an
estimated 1 in every 100,000 cases of cancer, compared to 25 in every 100,000 cases in parts of
China (13).

Laryngeal and hypopharyngeal cancer. The larynx, or voice box, is the opening into
the trachea from the pharynx and functions in respiration, swallowing, and speech (14). The
hypopharynx, which makes up the lower region of the pharynx, is located just above the larynx
and helps in respiration (15). As with other cancers of the head and neck, the majority of
laryngeal and hypopharyngeal cancers are squamous cell carcinomas (16; 17). However, other
types, such as adenocarcinomas, may also occur (17).
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In 2015, there is estimated to be over 13,500 new cases of laryngeal cancer in the United
States, and that there will be approximately 3,400 new cases of pharynx cancer that will start in
the hypopharynx (7; 18). The rates of laryngeal cancer have been declining in recent years due to
the reduction of smoking in the US population (19).

Epidemiology of Head and Neck Cancer
Worldwide, there is variation in the rates of the disease between populations. For men in
developed countries, the age standardized rates for oral cavity, pharynx, and larynx cancers range
from 5.1-7.9 in more developed regions, compared to 3.4-5.7 in less developed regions (20). For
females in more developed regions, the age standardized rates of these cancers ranges from 0.72.4, compared to 0.6-3.5 in less developed regions (20).
Though relatively rare in the US, the burden of HNC is still significant. It is estimated
that there will be nearly 60,000 new cancer cases of oral cavity, pharynx, and larynx cancers
combined, with over 43,000 of these new cases in males and nearly 16,000 in females (7).
Combined, these cancers will be associated with over 12,000 deaths (7). Further, HNC carries a
significant financial burden, with the estimated direct medical costs in the US for HNC patients
was over $3.6 billion in 2010, with nearly equal indirect costs associated with factors such as
work loss in these patients (21).
In the US, the rates of certain HNCs have been on the decline in recent years, while other
HNCs have remained steady or are on the rise. For instance, cancer of the larynx has been
declining by 2.4% annually over the last decade (22), likely due to decreases in tobacco use.
However, oropharyngeal cancers have shown increases in recent decades, which is thought to be
associated with human papillomavirus (HPV) in the population (23; 24). Though improvement in
HNC survival has been seen in recent years (25), the survival of HNC remains low, with five-year
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survival estimates around 60% (26). Five year relative survival for larynx cancer ranges from
35.2%-75.9% depending on stage of cancer, while five year relative survival for cancers of the
oral cavity and pharynx ranges from 37.7%-83.0% (26).
The incidence and associated mortality of HNC in the US have, overall, shown
downward trends. However, within certain subpopulations and cancer sites, these trends are not
consistent. For example, Kingsley et al (2008) found that the incidence of oral cavity cancer in
Black females from 2000–2004 increased by over 3% (20; 27). Further, Gayar et al. found
increases in the incidence of oropharyngeal carcinoma among white men from 1973-2009, but a
decrease in incidence during this same time period among Black men (24). These examples may
be indicative of the changes in risk factors and behaviors associated with the diagnosis of HNC
based on sociodemographic differences.

Risk Factors for Head and Neck Cancer
HNCs as a group have been associated with a number of risk factors for their
development. There are two major risk factors associated with HNC diagnosis: substance abuse
(alcohol and tobacco) and HPV (1). Though these risk factors tend to be discussed most
frequently in the literature, other risk factors that have also been linked to HNC as described more
in details in the following sections.

Tobacco and alcohol use. Substance use, specifically alcohol and tobacco use, is a major
risk factor for HNC (2). The risk for developing HNC has been shown to be as high as 25 fold
higher for in those who smoke cigarettes than nonsmokers (28; 29). Further, alcohol consumption
has been associated with a twofold higher risk of HNC development compared to those who do
not consume alcohol (2). While both tobacco and alcohol use alone have been shown to be
independent risk factors, the attributable risk of HNC for the combination of use has been shown
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to be approximately 75-80% in past literature, indicating there is a synergistic effect (2; 29). As
risky lifestyle behaviors, such as smoking, have declined in the United States, so have their
associated cancers, including some forms of HNC. However, new risk factors are being identified
in relation to HNC incidence.

Infections. Certain viral infections have been found to be associated with HNC
development. Epstein Barr Virus (EBV) has been shown to be associated with different cancers in
humans, including NPC. NPC is more common in areas where the incidence of EBV is high,
including some African and Asian countries, especially Southern China (30).
HPV has also been found to be associated with several types of HNC, including oral
cavity, laryngeal, and hypopharyngeal cancers, but the relationship is inconsistent and not clearly
related to causation. HPV, particularly subtypes 16 and 18, is most frequently associated with
oropharyngeal cancers (2). Recent studies on HPV, specifically subtype 16, have suggested that
this virus may be an independent risk factor for oropharyngeal carcinoma arising in the palatine
and lingual tonsil tissue (31). Further, HPV-associated HNCs are distinct from non-HPV
associated HNCs in terms of presentation and prognosis (2).
The impact of infection on cancer incidence varies by both cancer site, as well as
geographic location. The global estimated population attributable fraction (PAF) of EBV
infection for NPC is 85.5%, with a greater number of attributable infections in less developed
regions. For oropharyngeal cancer, the PAF of HPV infection is 25.6%, but there are a greater
number of attributable infections in more developed regions (32). These variations are largely due
to the prevalence of HPV infection in these areas, and may change in response to increasing rates
of HPV in the future.

Age, gender, and race. There are differences in HNC incidence across age and gender.
While there are differences based on specific location and subtype, like many other cancers,
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HNCs are more likely to be diagnosed in individuals aged 50 and older (33; 34). Based on data
from the National Cancer Database (NCDB), in the US, nearly 70% of all HNCs occur in
individuals over the age of 50 (34). However, data from the NCDB also showed that a decline in
the proportion of squamous cell cancers among older adults, and a greater proportion of HNC
cases in individuals aged 40-49 years of age (34), which likely is a manifestation of increasing
HPV-associated cancers of the oropharynx and a decline in tobacco-associated cancers.
There are also notable gender and racial differences in HNC incidence. In general, the
male-to-female ratio for HNC is 2:1 to 5:1 (35). However, in recent years, the gap between the
genders has started to narrow slightly, with declines in HNC incidence being more dramatic in
males compared to females (36), likely due to declining rates of substance use (37). Further, there
are racial differences in HNC incidence and mortality in the US, with Blacks bearing a greater
burden compared to Non-Hispanic Whites (38).

Other risk factors. Many other factors have been associated with an increased risk of
HNC. Certain genetic factors have been associated with greater risk of HNC, including
polymorphisms in genes involved in tobacco and alcohol metabolism (2). Further, studies have
found that individuals with a family history of HNC are at increased risk for HNC diagnosis (39).
Certain environmental and occupational exposures such as asbestos and cement, as well as certain
heavy metals such as nickel and chromium, have been identified as potential risk factors for
HNCs (40; 41).
Other factors have also been associated with HNC diagnosis. Lower body mass index has
also been associated with increased risk of HNC, even after controlling for tobacco and alcohol
use (42). Similarly, diet has been found to be associated with HNC, with higher consumption of
red or processed meats associated with a greater risk of HNC, and higher consumption of fruits
and vegetables associated with a lower risk of HNC (43). Additionally, due to the association
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between HPV and HNC, sexual history and number of sexual partners has also been found to be
associated with increased risk for HNC (44).

Diagnosis of Head and Neck Cancer
Depending on stage and site, HNC can sometimes be difficult to identify because of
vague symptoms and location. Symptoms of oral cancers often include non-healing sores in the
oral cavity, while those of the pharyngeal cancers include symptoms such as sore throat, trouble
swallowing, or pain in the ear (28; 35).
The diagnosis of HNC may vary by specific site of cancer within the HNC group.
However, in general, diagnosis begins with a general physical examination, with a health care
provider examining all areas of the oral cavity, as well as the nose, ears, scalp, and lymph nodes
(2; 28). Endoscopy may then be performed for examination of areas such as the nasal cavities,
base of the tongue, larynx, and pharynx (2; 28). Biopsies may be taken from any abnormal areas
for further confirmation (2; 28).
Once cancer is confirmed, there are several tests which can be used to examine the
extent, or stage, of the disease. Computed tomography (CT) is often performed for this purpose,
as well as positron emission tomography (PET) (28). Other tests may also be performed,
including x-ray to examine potential spread to the bone, chest imaging for those at risk for distant
metastases and molecular and HPV testing of the tumor to guide treatment (2; 28; 45).

Staging and Treatment of Head and Neck Cancer
The American Joint Commission on Cancer (AJCC) TNM staging system is often used
for HNC staging (28). This system utilizes information on tumor size and location, information
on lymph node spread, and cancer metastasis to stage cancer. Though differences in classification
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may occur based on specific cancer site, in general, the “T” classifications range from T1 to T4
depending on size and location of the tumor, with T1 representing the least advanced stage and
T4 representing the most advanced stage. For this classification, T4 describes advanced stages of
the disease where the tumor has invaded adjacent structures. The “N” classifications range from
N0 to N3, with N3 describing metastasis in a lymph node > 6 cm in greatest dimension. Finally,
the “M” classifications range from M0 to M1, where M1 indicates the presence distant metastasis
and M0 indicates none (28; 45). Together, these cancer characteristics are used in helping to
determine the stage of HNC.
The specific treatment of HNC depends on the site and stage of cancer, side-effects of
treatments, and patient demographics and preferences (28; 45). Treatment for HNC can involve
surgery, radiation, chemotherapy, or some combination of these (28; 45). Single-modality therapy
is the goal when possible. Generally, cancers in the early stages are treated with surgery or
radiation (28). For more advanced stages, HNC is often treated with surgery, if possible, followed
by radiation with or without chemotherapy, or with concurrent chemoradiation when tumor
resections not advisable (28).
The diagnosis and treatment of HNC is a very complex and multifaceted process. As with
other cancer, treatment for HNC often involves a multidimensional team approach, utilizing the
knowledge and skills of different healthcare professionals. Those involved in the treatment of
HNC may include oncologists, radiologists, and surgical oncologists for the eradication of cancer;
plastic surgeons, prosthodontists, and physical and speech therapists for physical construction and
rehabilitation; and psychologists and social workers for the psychological and emotional health of
patients (45).
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DEPRESSION IN HEAD AND NECK CANCER

Cancer and Depression
Cancer diagnosis and treatment often cause psychological distress for patients. As a
result, there is a significant body of literature on the relationship between cancer and mental
health disorders, including anxiety, adjustment disorders, and posttraumatic stress disorder
(PTSD) (46; 47). However, depression, both diagnosis and symptomology, has received the most
attention of any psychological illness in previous oncology literature (48).
Depression is common among cancer patients. In a recent meta-analysis, the prevalence
of depression in cancer patients ranges from 8% to as high as 27% (49). Further, it has been
estimated that the occurrence of major depressive episodes among cancer patients is
approximately two to three times higher than in the general population (50). Overall estimates
show that the prevalence of major depression in cancer patients range from 3% to as high as 38%
and that depressive spectrum syndromes among cancer patients may be as high as 52% (51). The
prevalence of depression varies by several factors including patient characteristics (such as
gender and age) depression assessment features (such as time of administration and type of
measurement), as well as clinical factors of cancer diagnosis (49; 52).
Not surprisingly, clinical features, including stage and specific site of cancer, have also
been shown to impact estimates of the prevalence of depression in cancer patients. Certain types
of cancer have been found to have a greater association with depression than others in previous
literature. HNCs, along with those of the brain, pancreas, breast, and digestive tract, have been
associated with higher rates of depression (49; 51). At the time of diagnosis, depression rates in
HNC have been estimated to be as high as 40%, and depression has been shown to afflict nearly
30% of HNC patients even three years after diagnosis (51; 53). The diagnosis and treatment of
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HNC have been associated with high morbidity in patients, including physical disfigurement, loss
of function, and reduced quality of life (51; 54; 55), all of which may help explain the increased
risk of depression among HNC patients. Further, lifestyle factors preceding cancer, such as
excessive tobacco and alcohol use, may be indicative of preexisting depression.

Depression Preceding Cancer
The relationship between depression and chronic illnesses, such as diabetes and coronary
artery disease, is thought to be reciprocal in that one may increase the risk of the other (56). There
are a number of factors associated with both depression and HNC, including excessive alcohol
and tobacco use and other poor lifestyle choices (57), which may put this particular cancer patient
population at higher risk for experiencing depression during cancer diagnosis and recovery.
However, these factors may also be signs of preexisting depression, indicating that preexisting
depression may put individuals at risk for developing cancers such as HNC. Because depression
can affect behavioral risk factors for cancer, there has been speculation as to whether depression
may influence the incidence of certain cancers (58).
Depression has been theorized to influence cancer development in one of several ways.
One theory is that depression may weaken the immune system causing the individual to be at
greater risk for disease development (59). Another is that chronic stressors associated with
depression may cause a decrease in deoxyribonucleic acid (DNA) repair enzymes and natural
killer cells important in apoptosis, therefore allowing malignant cells to grow (59). Others include
shared genes relating to both diseases, as well as shared behavioral risk factors (59). These
theories indicate the potential influence of depression on cancer development and suggest
potential areas of intervention to improve HNC outcomes.

11
While the reciprocal relationship between depression and other chronic diseases has been
shown (56) there is still significant debate about the reciprocity of depression and cancer, and
previous research on the topic has led to mixed results. In an examination of patients hospitalized
for depression in Denmark, the authors found that brain cancers and tobacco-related cancers, such
as lung cancer, were higher than expected in depressed patients, but that overall cancer incidence
in depressed patients was not significantly different from national cancer incidence rates (58).
The authors suggest the results may highlight the negative effect that depression and other mental
illness may have on health behaviors (58). Further, in a sample of 3,177 individuals in the United
States followed for 24 years, Gross et al. (2010) found an increased incidence of overall cancer
and hormonally-mediated cancers, including prostate and breast, among individuals with a history
of depression (59). However, the authors found no association between depression and other
cancers including colon, lung, and skin. Because there is still significant debate surrounding the
influence of depression on cancer development, additional larger, longitudinal studies are needed
to help understand the relationship between depression and cancer development.

Depression and Cancer Diagnosis
Understandably, the diagnosis of cancer can cause significant physical and psychological
distress. Cancer patients must cope with the physical changes, medical care and financial costs of
treatment, and time away from family and work. HNC patients may face a number of challenges
during diagnosis and treatment that may put them at increased risk of depression (54). The
diagnosis of HNC often carries significant stigma, as these cancers may be seen as self-inflicted
due to lifestyle choices (60). Further, individuals with depression may present with later stages of
cancer at the time of diagnosis, resulting in more intensive treatments, higher morbidity, and
poorer survival outcomes (61). Patients with HNC may be at increased risk of depression because
many diagnostic and treatment procedures of HNC lead to obvious physical disfigurement, loss of
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basic functions such as eating and speaking, and other negative side-effects of treatments (53). In
particular, radiation treatment may result in various side-effects that can impact the psychological
health of HNC patients.

Radiation Treatment and Depression
Radiation therapy, either alone or in combination with surgery, is the typical treatment
for HNC (62). Though these therapies have been proven to help decrease mortality in HNC
patients, radiation treatments are frequently associated with several side-effects unique to or more
severe in this patient population. There are a number of radiation side-effects that can impact the
daily lives and functioning of HNC patients.
Oral or dental related diagnoses have been reported in previous studies and may be
particularly pertinent to the HNC population (63). HNC patients undergoing radiation may have
oral and dental issues related to cancer itself, but also due to the radiation they receive. Patients
who receive radiation have been shown to have increased trouble producing saliva and
swallowing, concerns about social eating due to loss of functioning, dry mouth, increased risk of
dental caries, and oral infection (63; 64). Further, xerostomia, or dry mouth, has been shown to
significantly affect functioning and quality of life (65; 66). In fact, in a systematic review by So et
al. (2012), two of the three most commonly reported side-effects related to quality of life in HNC
patients were xerostomia and sticky saliva (66).
Weight loss, loss of appetite, and malnutrition have also been reported side-effects of
radiation treatment in HNC patients (67; 68). The HNC population has been shown to be at
increased risk for these side-effects compared to other cancer sites due to both the physical
obstructions and limitations that may be involved in HNC, as well as potential toxicities from
treatment (67; 68). Other common side-effects reported in HNC patients include fatigue, pain,
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and dermatitis (66; 69; 70). These can all negatively affect the psychological health of HNC
patients and, ultimately, patient outcomes.
Radiation has also been found to be associated with depression. In a randomized trial of
the antidepressant escitalopram for the prevention of depression in HNC patients, it was observed
that the development of depression was more likely to occur in those patients who received
radiation (71). Furthermore, recent evidence shows suicide risk is also substantially higher in
HNC patients who receive radiation as part of their treatment (72).

Depression and Survival Outcomes among Head and Neck Patients
Depression in HNC and other cancer patients can have a significant and lasting impact on
these individuals, and this impact can be seen both before and after cancer diagnosis. In general,
mental illness, such as depression, may lead to less frequent screening for cancer and therefore
later stage at diagnosis (73; 74). The diagnosis of cancer at later stages can result in more invasive
treatments and poorer survival probability for patients. In fact, previous research has shown that
depression in cancer patients results in lower quality of life and may affect survival outcomes (48;
75). Specific to the HNC population, studies have shown that individuals with HNC have a
substantially higher risk for completed suicide when compared to other cancers and the general
population (72; 76; 77).

Limitations of Previous Research
Previous literature looking at depression in HNC has estimated the proportion of
depressed patients in this cancer population to vary widely. This may be due to the differences
between these earlier studies, as well as the limitations of each. Many previous studies have used
smaller sample sizes, or single-site hospital-based samples for their research, which may not
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allow for representative estimates of depression of this population. However, the most significant
differences among many of these studies were the variation in how depression has been
measured.
Depression in previous literature among HNC patients has been assessed by a number of
different methods. In a systematic review done in 2009, the authors identified over ten different
inventories, scales, or symptom checklists used to assess depression in HNC patients in over 50
studies (53). Within each of these studies, even those that used the same inventory utilized
different cut-off scores for their definition of depression. Further, the type of assessment differed
amongst many of these studies and included self-report measures, symptom frequency checklists
administer by a third party, and diagnostic codes found in administrative data. The differences
among these studies make it difficult, not only to make comparisons among these, but also make
it difficult to compare the rates of depression between HNC patients and other cancer groups.
In addition to gaps in the literature regarding depression incidence or prevalence
estimates in HNC patients, there is also limited information on the prevalence of depression prior
to cancer diagnosis in this population. Further, there is scarce research examining the influence
that preexisting depression may have on the stage of cancer at the time of diagnosis in the HNC
population. A large population-based clinical/administrative database, such as the SEERMedicare linked data, offers a unique opportunity to examine depression diagnosis in cancer
patients in the US, both before and after cancer diagnosis, and help to understand the potential
reciprocal relationship between depression and HNC throughout the course of cancer.

SEER-Medicare Linked Database as a Unique Source of Depression Research
The Surveillance, Epidemiology and End Results (SEER) database is a surveillance
system designed to track cancer incidence and survival in the US (78). Data collection for this
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system began in 1973 and it has continued to routinely collect high quality data on cancer
incidence and mortality over the last four decades. The SEER data cover over 20 geographic
areas in the United States with 98% completeness, and is considered to be highly valid and
representative of the US population (79). While SEER data offers much valuable information on
cancer incidence and outcomes, by itself, it is not able to offer information on risk factors,
comorbidities, and certain treatments received by the cancer population.
Starting in 1991, SEER data began being linked to Medicare data in order to fill some of
the gaps in cancer research. Medicare is a form of public insurance offered to individuals 65 and
older in the United States, and is the primary insurer for approximately 97% of this population
(79). Medicare data offer demographic and clinical information on Medicare patients for things
such as inpatient and outpatient visits, hospice and home health care, and prescription medication
use (79). The SEER-Medicare data files are linked using a series of algorithms matching
individuals in the data using identifying information such as name, date of birth, and social
security number, and approximately 93% of those in the SEER data are successfully linked to
Medicare files (78).
SEER-Medicare linked data offer the benefit of having population-based cancer data as
well as longitudinal information on risk factors and comorbidities found in medical record files.
Because SEER-Medicare data offer information on medical diagnoses other than cancer, this
linked dataset has been used in previous studies in order to examine the associations between
depression and various cancer sites, including breast, prostate, and pancreatic cancers (61; 80;
81), and therefore may provide an opportunity to compare depression rates in HNC patients to
those of other cancer sites.
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Specific Aims
HNCs are a distressing group of cancers, both physically and emotionally. While there is
a significant amount of literature examining the relationship between cancer and emotional and
psychological health, this existing body of literature has not yet fully examined the influence of
depression on stage at diagnosis, the influence that treatment side-effects may have on depression
development in these patients, or the role of depression in the survival of HNC.
The purpose of this dissertation is to examine the psychological aspects of HNC in order
to fill these gaps in the literature. The first study of this dissertation (Chapter 2) examines the
existing literature concerning depression in cancer patients and aims to develop a conceptual
model to better understand the pathways to depression in the HNC population. Utilizing the
SEER-Medicare linked data, the aims of the second study of this dissertation (Chapter 3) are to:
(1) estimate the prevalence of depression two years before cancer diagnosis, (2) estimate the
incidence of emergent depression one year after diagnosis of HNC, and (3) compare stage of
HNC diagnosis by depression status. The third study (Chapter 4) aims to investigate the 5-year
survival of HNC patients by depression status, and the final study (Chapter 5) aims to examine
the association between radiation treatment side-effects and depression outcomes in HNC
patients.
Together, these studies will help to reexamine the existing assumptions of the
relationship between depression and HNC diagnosis, and provide population-level information on
the associations between depression and cancer outcomes. The results of these studies may help
to establish policies for screening for depression in HNC patients at the time of cancer diagnosis,
but also help in influencing cancer treatment choices based on the risk of depression development
and standards for continued screening for depression during cancer treatment and recovery.
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CHAPTER II
CONCEPTUAL MODEL DEVELOPMENT TO UNDERSTAND THE PATHWAY TO
DEPRESSION AMONG HEAD AND NECK CANCER PATIENTS

Abstract
This paper proposes a conceptual model to understand the development of depression in
head and neck cancer patients. We conducted literature reviews of existing conceptual models of
depression among chronic disease patients and risk factors of depression in cancer patients. The
resulting model shows that both individual and contextual level factors can directly and indirectly
affect depression outcomes. Additionally, depression diagnosis may also impact treatment
decisions and lead to poor survival outcomes. The resulting model can help guide future research
in this and other cancer populations, and be used to develop targeted interventions for depression
in cancer patients.

Background
While cancer patients in general have been shown to be at risk for depression, head and
neck cancer (HNC) patients experience a number of risk factors for mental illness that are unique
to this group of cancers (82). Patient lifestyle preceding cancer often includes a history of
substance use and other high-risk behaviors (57). These behaviors may put individuals at
increased risk not only for cancer development, but also at increased risk for mental illness both
before and after cancer diagnosis. Upon cancer diagnosis, HNC patients may be forced to contend
with feelings of guilt knowing that their past behaviors may have predisposed them to cancer, and
may experience shame and stigma associated with an HNC diagnosis (83). During treatment and
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recovery, HNC patients are often left with functional impairment and physical disfigurement as a
result of their treatments (57; 84; 85), as well as the struggle associated with withdrawal and
abstinence from tobacco and alcohol use (86). Though cancer diagnosis has been associated with
a variety of mental illnesses, including anxiety and post-traumatic stress disorder (46; 47),
depression may be one of the most prevalent comorbidities in the cancer population (48).
Previous research has shown that depression may affect anywhere from 9-54% of HNC
patients during the course of cancer and recovery (53). Preexisting depression has been linked to
a lower survival, worse nutrition and lower quality of life in HNC patients (87) . In a prospective
depression prevention trial, emergent depression was strongly associated with radiation therapy
(88). Further, the rate of suicide in HNC patients has been estimated to exceed most other cancer
sites, with rates estimated at 53.1 and 46.8 per 100,000 person-years for oral cavity/pharynx and
larynx cancers compared to 32.4 for all cancers sites combined (72; 77). Suicide appears to be
especially high in patients that receive radiation therapy (72). Based on existing literature, there is
an apparent connection between depression and HNC, both before and after cancer diagnosis.
However, although contributing factors in this population have been identified, the pathway to
how these factors influence depression development is not well understood and the need for a
more methodical understanding is acute.
In health research, conceptual models help to provide a way of unifying and organizing
ideas to help structure the design and interpretation of studies (89). Additionally, conceptual
models can aid in research design and offer clinical utility in understanding disease development
and prognosis. While several conceptual models have been proposed to understand the
association between depression and cancer, very few have focused specifically on the HNC
population.
In their article on depression in HNC patients, Archer et al. developed a conceptual
model to understand the pathways linking depression and oral cancer, focusing heavily on the
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biological components of the disease. After a review of the literature, the authors concluded that
preexisting depression had no effect on cancer incidence. However, the authors developed a
model to explain the possible effects of stress-hormone activity and increased cytokine levels that
may lead to increased risk of mortality in cancer patients with depression (82). Emphasizing more
of psychosocial aspects of disease, Frampton described a conceptual model centering on factors
relating to psychological distress in relation to the diagnosis of treatment of HNC (90). In this
model, the author included factors such as body image, social stress, and history of psychiatric
illness in the development of psychological distress in HNC patients. Additionally, Llewellyn et
al. used the common sense model framework to describe how HNC patient beliefs about their
illness influence outcomes such as depression of quality of life (91). While each of these models
offers insights into the relationships between HNC and depression, they concentrate mostly on
depression after cancer diagnosis and, therefore, do not fully explain the relationship between
HNC and depression.
The purpose of this paper was to develop a conceptual model examining the associations
between depression and HNC at various time points, both before and after cancer diagnosis.
Using the current literature of depression development in cancer and other chronic diseases, as
well as the existing body of knowledge of factors contributing to depression in HNC, we have
developed a conceptual model to understand the development of depression in HNC patients and
its influence on cancer outcomes in this population.

Methods
A literature search was conducted to identify existing conceptual models of depression
among chronic disease patients and risk factors of depression in cancer patients. Articles were
identified by literature database searches of MEDLINE and EMBASE from January 2000-May
2015. Keywords that were searched included the following: conceptual model, conceptual
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framework, cancer, depression, and head and neck cancer. In order to incorporate known factors
associated with depression in HNC patients, a second literature search was conducted utilizing
MEDLINE and EMBASE databases from January 2000-May 2015using the keywords depression
and head and neck cancer. The searches were limited to humans and articles in English.
Relevant articles were reviewed and variables associated with depression in chronic
disease patients were extracted from the literature. From these variables, those relevant to the
HNC population were incorporated into the model. Articles utilizing conceptual models or
theoretical frameworks were reviewed and relevant aspects were incorporated into the proposed
conceptual model at various time points over the course of cancer diagnosis and treatment. Using
previous models as a framework and previous literature identifying factors associated with
psychological health in HNC patients, we developed a conceptual model of depression in HNC
focusing on both the effects of depression prior to cancer diagnosis, as well as the development of
depression following cancer diagnosis. Factors that were related to HNC patients were included
in the model

Results
Our search for conceptual models for depression and cancer or HNC resulted in a total of
203 unduplicated articles between the searched databases. All abstracts were reviewed for
relevance, and citations of relevant publications were examined to identify any articles missed in
the search. This resulted in a total of 47 articles that utilized or developed conceptual or
theoretical models concerning cancer patients and other chronic diseases with some incorporation
of the psychological aspects of the disease. The search for depression and HNC resulted in 426
unduplicated articles across the databases. Of these, 85 articles were identified which examined
risk factors for depression development in HNC or identified implications of depression in HNC
patients. Table1 gives a listing of the various factors influencing depression in HNC patents
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before and after cancer diagnosis, and Figure 1 shows the proposed conceptual model based on
our synthesis of the literature. As can be seen from the model, we included factors influencing
depression prior to cancer diagnosis as well as the influence that cancer diagnosis may have
depression development. The proposed model incorporates a number of variables found in
previously proposed models for depression in cancer patients, as well as risk factors that have
been identified in previous literature.

Previous models. Our literature search resulted in a number of articles that utilized
conceptual models or theoretical frameworks which incorporated psychological aspects of cancer
and other chronic diseases. While several models and frameworks were utilized, the majority of
these incorporated aspects of transactional theory related to stress, appraisal, and coping. In this,
psychological symptoms are the response to the relationship between the individual and
environment, where the person sees the environment as taxing if there is a discrepancy between
situational demands and personal resources (92; 93). Theories focusing on unpleasant symptoms
and symptom management were also used as the theoretical framework for several publications
aimed at understanding performance outcomes in relation to the side-effects of HNC and other
cancers (94; 95). Additionally, applicable to the HNC population, Cataldo et al. developed a
conceptual framework surrounding the stigma associated with lung cancer, which incorporates
both the perception of attitudes toward smoking and smoking-related cancers, as well as personal
knowledge of the patient (96).

Factors influencing preexisting depression. A history of depression or depressive
symptoms has been associated with greater risk of depression at later time points over the course
of cancer diagnosis and treatment (97-100). In order to focus on the association between HNC
and depression prior to cancer diagnosis, factors associated with depression in HNC patients were
applied to the model showing depression development prior to cancer diagnosis. The left side of
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the model in Figure 1 shows the potential pathways for the individual and environmental
variables that may be risk factors for the development of depression prior to cancer diagnosis. As
can be seen in the model, individual differences such as family history of mental illness and
heredity (82), certain demographic factors such as gender, age, marital and employment status,
income (53; 101-103) religiosity or spirituality (104), and early childhood experiences (105) can
all affect the personality, coping style, and worldview of these individuals (106-110).
Environmental factors, such as family and social environment and patients’ social networks, can
also affect personality and worldview of an individual (86; 99; 111; 112). Together and
separately, these can affect depression development prior to cancer diagnosis, as well as exposure
to potential risk factors, such as smoking and alcohol consumption, which have been associated
with depression in HNC patients (113).
Factors such as having a positive social environment and social support, and higher
education may reduce the likelihood of risky behaviors associated with depression and the
development of HNC (e.g. smoking and alcohol consumption) (104) or having fewer
comorbidities and greater overall self-care (53; 114). As can be seen in the model, these not only
impact the personality and world view of the individual, but may also affect the diagnosis of
preexisting depression and HNC. For example, improved social support may lead to a lack of
addiction to tobacco and alcohol that may, in turn, continue to improve this level of social support
and improve mental and physical health.

Factors influencing depression after cancer diagnosis. After cancer development and
diagnosis, individual and environmental factors continue to influence the risk of depression
development in HNC patients. Factors listed on the left-hand side of the model can continue to
influence depression status after cancer diagnosis. Additionally, individual factors, such as fear or
shame concerning the diagnosis (115; 116), as well as clinical factors, such as the specific site
and stage of cancer, may influence patients’ mental health and coping (86; 117-119). Medical
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comorbidities and functional status of patients may also influence psychological health (120-124;
85).
Likewise, other environmental factors may affect depression status of patients after
cancer diagnosis. Emotional and social support continue to play a role in depression in HNC
patients (107; 112; 124-126), as well as experiencing social stigma related to the disease (60).
Previous literature has also shown that satisfaction with information provided by healthcare
workers may be associated with better depression outcomes in this patient population (107; 127).
Because of this, patients’ relationship with healthcare providers was included in the model as part
of the environmental factors impacting depression outcomes.
Treatment side-effects appear to play a significant role in depression development in
HNC patients. Side-effects of treatment such as pain, fatigue, and sleeping difficulties (128- 135)
speech difficulties (123; 136-138) xerostomia, dysphagia or other swallowing difficulties (134;
138-142) and trouble eating, loss of appetite, and malnutrition (123; 134; 143-145) have all been
shown to be associated with the psychological health of HNC patients. Further, surgery and
disfigurement have also been associated with depression development in HNC patients, in part in
relation to the loss of function, as well as concerns about body image (146-148). Finally,
increases in symptoms, as well as receipt of radiation and the associated side-effects of this
treatment, have been associated with greater risk of depression (62; 149).
In the proposed conceptual model in Figure 1, individuals may experience side-effects
associated with treatments, which may vary by cancer site. Patients who are unable physically
manage these side-effects or emotionally cope with them may be affected by individual and
environmental factors, such as personal shame and social support, but this relationship can be
seen as bidirectional, as their inability to cope can also affect these factors. As an example, a
patient who experiences a side-effect of trouble with saliva production may feel uncomfortable in
social eating situations, causing personal shame (139; 140; 144). This may lead to the patient
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removing themselves from social situations, which limits their social supports and may lead to
depression.

Factors influencing HNC outcomes. In terms of depression status and HNC outcomes,
as is shown in the model, these can be affected by the individual and environmental factors of
earlier parts of the model (such as cancer stage, medical comorbidities, or economic factors), as
well as treatments received. The individual and environmental factors presented earlier in the
model may influence patients’ ability to cope with the side-effects of treatments that may also be
associated with overall better self-care. For example, greater education, supportive family
environments, and greater resources such as income and insurance may be associated with
improved self-care in these patients and, therefore, better treatment adherence. Additionally,
these may be associated with reduced likelihood of returning to prior risky behaviors, such as
tobacco and alcohol use (150-152), therefore, improving outcomes.
Depression has been shown to affect treatment decisions of cancer patients (81), which
can affect mortality rates of these patients. Further, psychological morbidity has also been shown
to be associated with a greater fear of recurrence in HNC patients (116). Finally, several studies
have shown that HNC patients who are depressed may have overall lower quality of life (124;
135; 153; 154), are at greater risk for suicide (72; 76), and have overall worse survival (75; 155).
Because of the influence that depression may have on quality of life and survival of HNC
patients, identifying and treating depression in this patient population may be important for
improving current survival treads of HNCs.

Discussion
HNC is especially distressing for patients diagnosed with these cancers. Patients with
HNC may struggle not only with the physical effects of the disease and its treatments, such as
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functional impairment and physical disfigurement, but the psychological effects as well. In
addition to the influence of any cancer diagnosis, this particular cancer population may be at
increased risk for psychological illnesses, such as depression, because of the shared risk factors
for these diseases. Additionally, depression diagnosis prior to cancer may leave these individuals
at an increased risk for depression recurrence after cancer diagnosis. Further, survival has been
shown to be lower in patients with preexisting depression (87). Understanding the complex
relationship between depression and HNC is crucial for future studies in this field.
As can be seen in the proposed model, there are many individual and environmental
factors that can influence the diagnosis of depression in the HNC population. Factors such as
demographics of the patient, social support and network, and clinical variables related to cancer
may all play a role in the development of depression in HNC patients. In the model proposed in
this paper, depression can be seen as both a risk factor for and the result of the diagnosis of HNC,
and therefore, may be helpful in understanding the full relationship between depression and HNC.
Previous literature indicates that cancer patients may not be forthcoming about their
emotional wellbeing during consultations with their physicians (156). Moreover, physicians may
only briefly discuss psychological or emotional issues with patients, even when patients voice
concerns (157). The proposed conceptual model may help physicians and other healthcare
workers to not only identify HNC patients who may be at increased risk for depression
development, but also to help them understand the effect that depression can have on cancer
outcomes of their patients.
Depression has been associated with worse treatment outcomes and poorer quality of life
in HNC patients. Identifying the pathways by which depression may develop and influence
patient outcomes is an essential step toward prevention. The model proposed can help guide
future research in this and other cancer populations, and be used to develop targeted interventions
for depression in cancer patients.

Stigma
Relationship with medical professionals
Economic support

Family environment
Social environment
Social network
SES

Smoking/alcohol
Risky behavior
Poor health
Reduced social contact
Reduced self-care

Environmental-Level
Factors

Social/Behavioral Risk
Factors

Continue smoking/ alcohol
Poor health
Reduced social Contact
Reduced self-care
Fear of recurrence

Fear/shame
Decision making style
Disease knowledge
Site & stage of cancer
Medical comorbidities
Functional status
Other life stressors
Treatment received/receipt of radiation

Demographics
Family history and heredity
Social support/ marital status
Income/employment status
Education
Health
Religion/spirituality
Early life experiences

Factors influencing Depression after
Cancer Diagnosis and HNC Outcomes

Individual- Level
Factors

Factors influencing Preexisting Depression

Table 1. Factors influencing depression development in HNC patients
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Figure 1. Proposed conceptual model of the pathway to depression among HNC patients
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CHAPTER III
POPULATION-BASED RETROSPECTIVE STUDY TO INVESTIGATE PREEXISTING
AND NEW DEPRESSION DIAGNOSIS AMONG HEAD AND NECK CANCER
PATIENTS

Publication Acknowledgement:
Rieke K, Boilesen E, Lydiatt W, Schmid KK, Houfek J, Watanabe-Galloway S. Population-based
retrospective study to investigate preexisting and new depression diagnosis among head and neck
cancer patients (In Press, Cancer Epidemiology; DOI:10.1016/j.canep.2016.06.008).

Abstract
This study aimed to estimate the pre-cancer prevalence and post-cancer incidence of
depression in older adult head and neck cancer patients. Using SEER-Medicare files, cancer was
identified from SEER data and depression diagnosis was identified using Medicare claims. Of
3,533 head and neck cancer patients, 10.6% were diagnosed with depression during the two years
prior to cancer diagnosis, and an additional 8.9% developed depression in the year following
cancer diagnosis. This study supports the critical need of screening for depression throughout
cancer diagnosis and treatment, as well as a preventative approach in depression development in
the older head and neck cancer patient population.

Introduction
Head and neck cancers (HNC) have been said to be more emotionally traumatic than
other types of cancers (57; 158). There are a number of factors shared between depression and
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HNC, including substance use and other poor lifestyle behaviors, which put this particular cancer
population at risk for experiencing depression (57). Additionally, HNCs can be especially
distressing because they can affect patients’ communication and functioning, and may cause
severe disfigurement (51; 53). Treatment options for HNC, such as radiation therapy, have also
been associated with increased emotional distress in HNC patients, potentially as a result of the
side-effects of treatment (62). Recent data demonstrates a higher incidence of depression in
patients receiving radiation as the primary modality compared with surgery in a randomized trial
(71). These findings suggest that the long-standing view of disfigurement as the primary cause of
emergent depression may need to be reconsidered in order to understand how psychiatric illnesses
impacts patient quality of life and survival.
The effects of depression in HNC patients can be severe. Studies have shown that HNC
patients are at higher risk for suicide compared to other cancers and the general population (76),
and may have poorer quality of life and survival (48; 75). Further, research on other cancer sites
has shown that poor mental health may lead to less frequent screening and later stage at (73; 74).
However, even with the shared associations of substance use and high emotional cost, there are
still knowledge gaps in the literature surrounding depression and HNC.
Though HNC patients may be at increased risk for depression, currently there is no
precise estimate of depression in this population. Previous studies, which have been mostly smallscale, have reported the prevalence to range from 9-54% (53). This wide range may be due to
differences between these studies such as sociodemographic characteristics, cancer site and
staging, and the time at which depression was measured. Additionally, many have used selfreported depression from various inventories with different cut-offs for the definition of
depression, making it difficult to make cross-study comparisons. There is limited information on
the effect that preexisting depression may have on cancer stage at the time of HNC diagnosis.
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Further, lack of longitudinal research has resulted in a limited understanding of depression
development and outcomes among HNC patients.
There is a clear need to explore the role of depression in HNC outcomes. To our
knowledge, there are no population-based studies that have examined rates of depression in HNC
patients at multiple time-points or the implications of preexisting depression on cancer stage at
diagnosis. The specific aims of the study were to: (1) estimate the prevalence of depression two
years before cancer diagnosis in an older adult head and neck cancer population using
Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data, (2) estimate the
incidence of depression one year after cancer diagnosis, and (3) compare stage of HNC by
depression status.

Materials and Methods

Study Sample. The sample consisted of individuals diagnosed with HNC from 20042005 who were linked to Medicare data. HNC was identified by International Classification of
Disease for Oncology, Version 3 (ICD-O3) codes: 000-009 ( lip), 021-023, 030-031, 039-041,
048-050, 058-062, 068-069 (oral cavity), 019-020,024, 028-029, 051-052, 090-091, 098-103,
108-109, 140, 142, 148 (oropharynx); 110-113, 118-119 (nasopharynx), 129-132, 138-139
(hypopharynx), and 320-323, 328-329 ( larynx). Individuals had to have HNC as their only
cancer diagnosis and be 67 years of age or older at diagnosis in order to ensure a minimum of two
years of Medicare enrolment prior to cancer diagnosis. Individuals had to be continuously
enrolled in Medicare Parts A and B for 24 months prior to HNC diagnosis until December of
2010 or their death, and could not be enrolled in a health maintenance organization (HMO)
during this same time period to avoid incomplete claims records (74; 81).
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Depression Identification and Statistical Analysis. From this group, diagnosis of
depression was identified using ICD-9-CM codes from Medicare claims data. ICD-9-CM codes
for depression included the following: 300.4 (dysthymic disorder); 296.2-296.24, 296.3-296.34
(major depression single or recurrent episode); 309.0, 309.1(adjustment disorder with depressive
symptoms or prolonged depressive reaction); 311 (depressive disorder not otherwise classified);
296.5-296.54 (bipolar I disorder, most recent episode or current depressed); 298.0 (depressive
type psychosis); 301.10 (affective personality disorder, unspecified); 301.12 (chronic depressive
personality disorder); and 301.13 (cyclothymic disorder). To be included in the preexisting
depression group, subjects had to have at least one inpatient, outpatient, or carrier claim diagnosis
of depression within the 24 months prior to HNC diagnosis. To be considered part of the postHNC depression group, participants could not have been diagnosed with depression before cancer
diagnosis and had to have a depression diagnosis within the year following cancer diagnosis.
Individuals diagnosed with cancer at death or autopsy were excluded from all analysis of postHNC depression because there was no possibility of depression development.
All sociodemographic information was taken from SEER data, with education and
income based on census tract. Receipt of radiation as part of the initial course of treatment was
included as a dichotomous variable. Medical comorbidity was measured using an adaptation of
the Charlson Comorbidity Index (CCI) developed for Medicare data, utilizing diagnostic codes
based on the Deyo method (159-161). Diagnostic codes from inpatient, outpatient, and carrier
claims during the 12 months prior to cancer diagnosis were used to calculate the index score.
Stage of cancer diagnosis was taken from the derived SEER Summary Stage.
Chi-square and t-tests were carried out to examine demographic differences between
those with and without depression, both before and after cancer diagnosis. Forward selection was
used to fit the multivariable logistic regression model to examine factors associated with
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depression at both time points. All data were analyzed using SAS version 9.3. This study was
approved by the University of Nebraska Medical Center Institution Review Board.

Results
From 2004-2005, 12,175 individuals were diagnosed with HNC. Of these, 2,951
individuals were excluded because HNC was not their only cancer diagnosis, and 4,315 were
excluded for being under the age of 67 at the time of HNC diagnosis. Another 151 individuals
were removed for not being continuously enrolled in Medicare Parts A and B during the study
period, and 1,225 were removed for being enrolled in an HMO at some point during the study
period. This left 3,533 individuals in the final sample.

Prevalence and Incidence of Depression. In total, 375 (10.6%) individuals were
diagnosed with depression during the two years prior to HNC diagnosis. Table 1 shows the
characteristics of the sample by preexisting depression status. The groups differed significantly
by gender, with a higher percentage of females in the depressed group (45.9% vs. 32.5%). The
groups also differed by race, with 89.9% of the depressed group being Non-Hispanic White,
compared to 83.5% of the non-depressed group. Additionally, the groups differed by marital
status, with 40.5% of depressed subjects being married vs. 52.0% of non-depressed subjects.
Conversely, 34.1% of depressed patients were widowed compared to 24.5% of the non-depressed
group. Finally, in the pre-HNC depression group, 20.3% of individuals had a CCI score of one or
more, compared to 6.3% of the non-depressed group.
To examine incident depression, we eliminated individuals with pre-existing depression
and those diagnosed with HNC at death or autopsy, leaving 3,157 individuals. Of these,
281(8.9%) had a depression diagnosis within the year following HNC diagnosis. Table 2 shows
the characteristics of subjects by post-HNC depression status. Again, there were significant
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differences in gender, with 40.6% of the depressed group being female vs. 31.7% of the nondepressed group. The groups also differed by age, with 35.2% of the depressed group being 70-74
years old compared to 27.8% of the non-depressed group. There were differences in receipt of
radiation, with 69.8% of the depressed group receiving radiation compared to 45.7% of the nondepressed group. Finally, there were differences in stage of cancer at diagnosis, with 19.2% of the
depressed group diagnosed with distant stage vs. 13.3% of the non-depressed group.

Multivariable Analysis. Table 3 shows the multivariable logistic regression examining
factors associated with depression prior to cancer diagnosis. The odds of having depression prior
to cancer diagnosis differed significantly by gender, with females having 1.59 (95% CI=1.26,
2.02) times the odds of pre-HNC depression compared to men after adjustment for other variables
in the model. Race was also associated with pre-HNC depression, with non-White patients having
lower odds of depression (OR=0.50; 95% CI=0.35, 0.72). Marital status of patients was also
significant, with those who were divorced/separated (OR=1.52; 95% CI=1.05, 2.21) or widowed
(OR=1.46; 95% CI= 1.11, 1.92) having greater odds of depression compared to those who were
married. CCI was associated with pre-HNC depression, with a score of one or more having 4.08
(95% CI= 3.02, 5.50) times the odds of depression compared to a score of zero. Finally, cancer
stage was associated with preexisting depression, with distant stage having 1.61 (95%CI=1.17,
2.22) times the odds of depression compared to local and or regional disease.
Table 4 shows the multivariable results examining factors associated with developing
depression within the year following HNC diagnosis. Age was significantly associated with the
development of depression after HNC, with those aged 70-74 (OR= 1.53; 95% CI=1.07, 2.18)
and 80-84 (OR= 1.53; 95%CI=1.01, 2.31) having greater odds of developing depression
compared to those aged 67-69. In terms of gender, women had 1.57 (95% CI= 1.21, 2.03) times
the odds of developing depression compared to men. Receiving radiation was associated with
1.86 (95% CI= 1.40, 2.46) times the odds of developing depression compared to those who did
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not receive this form of treatment. Finally, in terms of cancer stage, those with distant stage had
1.72 (95%CI=1.20, 2.47) times the odds of developing depression compared to the non-metastatic
group. Potential interactions of gender with race and marital status were examined with no
significant associations found.

Discussion
The results of this study show that the prevalence of depression diagnosis during the two
years prior to HNC diagnosis in older adults was approximately 10.6%. This is slightly higher
than the prevalence found in SEER-Medicare studies focusing on other cancer sites older adult
head and neck cancer population. Boyd et al. (2012) (61) found that approximately 7.9% of
pancreatic adenocarcinoma patients had a depression diagnosis during the 3-27 months preceding
cancer, while Goodwin et al. (2004) (80) found that approximately 7.5% of breast cancer patients
had a pre-existing diagnosis of depression during the two years prior to cancer, and Prasad et al.
(2014) (81) found that approximately 5% of prostate cancer patient had a depression diagnosis
during this time period. Though the methodologies of these studies were not identical, it appears
that individuals with HNC may have a modestly higher prevalence of depression before cancer
diagnosis. Additionally, the present study found that the incidence of depression was 8.9%,
indicating that almost 9% of individuals without a depression diagnosis prior to HNC were
diagnosed with depression within one year of cancer diagnosis. This is likely a conservative
estimate of depression after HNC diagnosis, since this estimate does not include those who were
part of the preexisting depression group, which may be at risk for continued or recurrent
depression. Together, the results of this study show the burden of depression in the HNC
population, both at the time of cancer diagnosis as well as during treatment and recovery.
This study also showed differences in depression based on gender and race. Gender was
significantly associated with diagnosis of depression before and after cancer diagnosis, with
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females having higher odds of depression. This is consistent with previous literature indicating
that women may be more likely to experience depressive symptoms, or at least are more likely to
express them to their physician, especially in relation to cancer (74). Similarly, in the
multivariable analysis, being Non-Hispanic White was shown to be significantly associated with
depression diagnosis prior to cancer. These results may help in the identification of individuals
who may be at increased risk for depression.
The results of this study also indicated that individuals who were divorced/separated or
widowed at the time of cancer diagnosis had greater odds of experiencing depression prior to
HNC compared to those who were married. This may be indicative of a lack of social support,
which has been previously shown to be associated with increased emotional distress in HNC
patients (162). Additionally, higher medical comorbidities were associated with depression prior
to cancer diagnoses. While the interaction of marital status and comorbidity score was not shown
to be significant in the present study, social support may be a common thread among these
variables in their association with depression.
The data showed that individuals receiving radiation as part of their first course of
treatment had significantly greater odds of developing depression within one year of cancer
diagnosis. Previous studies have found that radiation treatment may cause a number of sideeffects including trouble swallowing, dental issues, and trouble hearing (63; 107; 163; 164). It is
possible that these side-effects may impact patients’ emotional well-being, putting them at risk
for depression. Additional factors that may be at play include systemic Il-6 elevation or chronic
unremitting stress during and after radiation therapy (165).
Age at the time of cancer diagnosis was also shown to be associated with depression
development. While the overall association was not shown to be significant, the 70-74 and 80-84
age groups differed significantly from the 67-69 age group. However, the estimates associated
with each age group were inconsistent in the direction of their association. While, in general,
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younger age has been associated with depression in HNC patients (57) it is possible that the
restricted age range of this study (age 67+) did not allow linear comparison by the assigned age
groups.
Finally, highly advanced stage at diagnosis was shown to be significantly related to
depression, both before and after cancer diagnosis. The implications of this finding are that
having preexisting depression may lead to poorer self-care and therefore less frequent physician
visits, leading to later stage at diagnosis. After cancer diagnosis, stage may be indicative of
severity of cancer and its side-effects, as well as fear of associated mortality, and therefore lead to
depression.
Targeted approaches to diagnose or prevent depression are urgently needed in patients
undergoing therapy for cancer, and HNC patients are at particular risk. This data supports earlier
literature of the profile of patients at high risk to develop depression, and thus, trends towards the
divorced/separated or widowed, white female with comorbidities and later stage of diagnosis who
will receive radiation therapy as a primary treatment modality. However this is not to say that
others are not at risk.
In terms of study limitations, SEER- Medicare files only offer diagnostic codes to
identify depression. Though we found that nearly 19% of this population was diagnosed with
depression during the study period, previous studies have found that as high as 54% of the HNC
population may have some form of depression (53). Utilizing diagnostic codes to identify
depression may not capture all cases of depression, such as those with subclinical symptoms or
those who never received a recorded diagnosis, which may underestimate the rates of depression
in this cancer population. Similarly, SEER-Medicare files only offer diagnostic codes for
variables concerning substance abuse. While previous literature has shown that diagnostic codes
for substance abuse disorders are reliable for psychiatric patients (166), patients with mental
illness may be more likely to receive substance abuse diagnoses than the general population,
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regardless of substance usage. Because of this, we chose not to examine substance abuse in
relation to depression outcomes. Additionally, Singer et al. found that HNC patients may
experience greater emotional distress compared to other cancer sites, but that this relationship
may be confounded by the level of perceived social support (162). Because SEER-Medicare data
does not offer any information on this construct, the effects of social support were not examined
in this study. Finally, restricting the age at diagnosis to 67 years and older eliminated more than
half of all HNC patients, so the study results cannot be generalized to younger HNC patients.

Conclusions
This study found that the prevalence of depression diagnosis in older adults prior to
cancer was 10.6%; modestly higher than in previous studies examining depression in other cancer
sites using SEER-Medicare data. Additionally, we found that approximately 9% of older adult
HNC patients had newly diagnosed depression within one year of cancer diagnosis. These results
support the need for depression screening within this population. It also adds credence to the
concept of a prevention approach in HNC patients. Given the significant associations of receipt of
radiation and depression outcomes in this study, there is a need to understand how this treatment
and its side-effects may affect depression development. Additionally future research of
depression in HNC patients should focus on the impact that depression has on survival and
quality of life, as well as identify interventions to prevent post-HNC depression in this patient
group.
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Table 1. Demographics by pre-HNC depression diagnosis
Variable
Age
67-69
70-74
75-79
80-84
85+
Gender
Male
Female
Race
Non-Hispanic white
Other
% of census tract with 4 year
college degree
0-33%
34+%
Unknown
Marital status
Married/Living as
Separated/Divorced
Single
Widowed
Unknown
Median census tract income
< $35, 000 or Missing
$35, 000- $44,999
$45, 000- $59,999
$60, 000+
Cancer site
Lip
Oral Cavity
Oropharynx
Nasopharynx/Hypopharynx
Larynx
SEER region
Pacific/West
Northeast
Midwest
South

Yes (N=375)
%

Number

%

Number

61
108
75
70
61

16.3%
28.8%
20.0%
18.7%
16.3%

671
899
696
484
408

21.2%
28.5%
22.0%
15.3%
12.9%

203
172

54.1%
45.9%

2,133
1,025

67.5%
32.5%

337
38

89.9%
10.1%

2,637
521

83.5%
16.5%

254
93
28

67.7%
24.8%
7.5%

2,260
723
175

71.6%
22.9%
5.5%

152
43
32
128
20

40.5%
11.5%
8.5%
34.1%
5.3%

1,642
284
274
775
183

52.0%
9.0%
8.7%
24.5%
5.8%

124
87
80
84

33.1%
23.2%
21.3%
22.4%

1,005
723
714
716

31.8%
22.9%
22.6%
22.7%

26
105
101
36
107

6.9%
28.0%
26.9%
9.6%
28.5%

248
731
841
283
1,055

7.9%
23.1%
26.6%
9.0%
33.4%

156
64
47
108

41.6%
17.1%
12.5%
28.8%

1,201
637
435
885

38.0%
20.2%
13.8%
28.0%

299
76

79.7%
20.3%

2,960
198

93.7%
6.3%

<0.001

0.001

0.185

<0.001

0.934

0.179

0.363

CCI
0
1+
Stage
Unstaged
In Situ/Localized
Regional
Distant

CCI= Charlson Comorbidity Index score

No (N=3,158)
p-value
0.043

<0.001

0.057
51
149
107
68

13.6%
39.7%
28.5%
18.1%

363
1376
983
436

11.5%
43.6%
31.1%
13.8%
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Table 2. Demographics by post-HNC depression diagnosis
Variable
Age
67-69
70-74
75-79
80-84
85+
Gender
Male
Female
Race
Non-Hispanic white
Other
% of census tract with 4 year college degree
0-33%
34+%
Unknown
Marital status
Married/Living as
Separated/Divorced
Single
Widowed
Unknown
Median census tract income
< $35, 000 or Missing
$35, 000- $44,999
$45, 000- $59,999
$60, 000+
Cancer site
Lip
Oral Cavity
Oropharynx
Nasopharynx/Hypopharynx
Larynx
SEER region
Pacific/West
Northeast
Midwest
South
CCI
0
1+
Radiation received
Yes
No
Stage
Unstaged
In Situ/Localized
Regional
Distant

CCI= Charlson Comorbidity Index score

Yes (N=281)
Number %

No (N=2,876)
Number %

52
99
52
52
26

18.5%
35.2%
18.5%
18.5%
9.3%

619
800
644
432
381

21.5%
27.8%
22.4%
15.0%
13.2%

167
114

59.4%
40.6%

1,965
911

68.3%
31.7%

240
41

85.4%
14.6%

2,396
480

83.3%
16.7%

197
72
12

70.1%
25.6%
4.3%

2,062
651
163

71.7%
22.6%
5.7%

131
23
29
83
15

46.6%
8.2%
10.3%
29.5%
5.3%

1,510
261
245
692
168

52.5%
9.1%
8.5%
24.1%
5.8%

84
63
69
65

29.9%
22.4%
24.6%
23.1%

921
659
645
651

32.0%
22.9%
22.4%
22.6%

18
66
80
24
93

6.4%
23.5%
28.5%
8.5%
33.1%

230
665
760
259
962

8.0%
23.1%
26.4%
9.0%
33.4%

98
73
40
70

34.9%
26.0%
14.2%
24.9%

1,103
563
395
815

38.4%
19.6%
13.7%
28.3%

263
18

93.6%
6.4%

2,696
180

93.7%
6.3%

196
85

69.8%
30.2%

1,563
1,313

54.3%
45.7%

27
98
102
54

9.6%
34.9%
36.3%
19.2%

335
1278
881
382

11.6%
44.4%
30.6%
13.3%

p-value
0.011

0.002

0.366

0.370

0.190

0.818

0.859

0.068

0.923

<0.001

0.002
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Table 3. Multivariable logistic regression of depression two years before HNC diagnosis
OR

95% CI

Gender
Males
Female

1.00
1.59

1.26

2.02

Race
Non-Hispanic white
Other

1.00
0.50

0.35

0.72

Marital status
Married/Living as
Single
Widowed
Divorced/Separated
Unknown

1.00
1.19
1.46
1.52
1.11

0.78
1.11
1.05
0.67

1.80
1.92
2.21
1.84

1.00
4.08

3.02

5.50

SEER region
Pacific/West
Midwest
Northeast
South

1.00
0.74
0.66
0.86

0.52
0.47
0.66

1.06
0.91
1.12

Stage
In Situ/Localized
Unstaged
Regional
Distant

1.00
1.38
1.04
1.61

0.96
0.79
1.17

1.98
1.36
2.22

p-value
<0.001

<0.001

0.052

CCI

<0.001
0
1+

CCI= Charlson Comorbidity Index score

0.055

0.013
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Table 4. Multivariable logistic regression of depression one year after HNC diagnosis
OR

95% CI

Age
Ages 67-69
Ages 70-74
Ages 75-79
Ages 80-84
Ages 85+

1.00
1.53
1.00
1.53
0.88

1.07
0.67
1.01
0.53

2.18
1.50
2.31
1.45

Gender
Males (REF)
Female

1.00
1.57

1.21

2.03

Race
Non-Hispanic white
Other

1.00
0.77

0.54

1.09

Stage
In Situ/Localized
Unstaged
Regional
Distant

1.00
1.12
1.29
1.72

0.71
0.95
1.20

1.75
1.74
2.47

Radiation received
No
Yes

1.00
1.86

1.40

2.46

CCI= Charlson Comorbidity Index score

p-value
0.012

<0.001

0.141

0.032

<0.001
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CHAPTER IV
DEPRESSION AND SURVIVAL IN HEAD AND NECK CANCER PATIENTS

Abstract

Objective. Though depression often afflicts head and neck cancer (HNC) patients, few
studies have examined the association between depression and survival in this particular cancer
population. The objective of this study is to investigate the five-year survival of HNC patients by
depression status.

Materials and Methods. This study used SEER-Medicare data from 2002-2010 and
identified depression diagnosis two years before and one year after cancer diagnosis. HNC
patients were identified using ICD-O3 codes and depression was identified using ICD-9-CM
codes from Medicare claims.

Results. Of the 3,466 patients included in the study, 642 (18.5%) were diagnosed with
depression during the study period. Compared to those who received no depression diagnosis,
those diagnosed with depression prior to cancer or after cancer diagnosis were more likely to die
of cancer (HR= 1.49; 95% CI=1.27, 1.76 and HR=1.38; 95% CI=1.16, 1.65, respectively).
Similarly, when looking at death from any cause, those diagnosed with depression prior to cancer
diagnosis and those who received a diagnosis of depression after cancer were more likely to (die
from any death compared to those without depression (HR= 1.55; 95% CI=1.36, 1.76 and
HR=1.40; 95% CI=1.21, 1.62, respectively).
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Conclusions. The results emphasize the need for early identification and treatment of
depression in HNC patients, as well as the establishment of policies to routinely screen these
patients throughout the cancer treatment process. Early detection and treatment of depression in
these patients may help to improve survival.

Introduction
Lower survival and poorer outcomes have been demonstrated in cancer patients with
depression (81; 167; 168). Previous studies examining depression in cancer populations have
found higher cancer recurrence and lower quality of life in cancer patients with clinical
depression or depressive symptomology (167; 169). Depression has also been associated with
increased mortality in patients with cancer, with mortality rates up to 25% higher in cancer
patients who experience depression (48; 170). Though previous studies have examined the effect
that depression may have on cancer mortality rates, there are few large-scale studies that have
examined the association between depression and survival in patients with head and neck cancers
(HNC).
HNC patients face unique psychological challenges compared to many other cancer sites.
HNCs and their treatments can cause severe physical and functional impairments, which have
been associated with depression development in HNC patients (51; 53; 106; 146). Further,
radiation therapy has been shown to be significantly associated with depression (102). Moreover,
patients with HNC may experience permanent facial disfigurement from treatments (106), and
unlike other cancer sites, patients may be left with visible scars or deformities that cannot be
concealed, which may cause issues with personal shame and self-consciousness, and ultimately
lead to depression (54; 83; 171).
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Because of the associations between HNC and depression, as well as the psychological
impact that these cancers and their treatments may have on patients, we previously examined
depression rates in HNC patients both before and after cancer diagnosis utilizing two linked
national datasets. The results of this study showed not only that depression diagnosis in HNC
patients was moderately higher than estimates from other cancer sites, but also that depression
was associated with advanced stage at diagnosis. However the question still remains as to the
effect that depression has on the survival of HNC patients. Therefore, the objective of the present
study is to investigate the five-year survival of HNC patients by depression status.

Materials and Methods
We utilized the Surveillance Epidemiology and End Results (SEER)-Medicare linked
data from 2002-2010. We identified all individuals diagnosed with HNC from 2004-2005 based
on International Classification of Disease for Oncology, Version 3 (ICD-O3) codes who were
linked to Medicare data. Individuals had to have HNC as their only cancer diagnosis and be 67
years of age or older at the time of diagnosis in order to ensure a minimum of two years of
Medicare enrolment prior to cancer diagnosis. Individuals had to be continuously enrolled in
Medicare Parts A and B for 24 months prior to their HNC diagnosis until December of 2010 or
their death, and could not be enrolled in a health maintenance organization (HMO) during this
same time period due to the possibility of incomplete claims records (74; 81).
From this group, diagnosis of depression two years prior to cancer diagnosis was
identified using ICD-9-CM codes from Medicare claims data. To be included in the preexisting
depression group, subjects had to have at least one claim diagnosis of depression within the 24
months prior to HNC diagnosis. To be considered part of the post-HNC depression group,
participants could not have been diagnosed with depression before cancer diagnosis and had to
have at least one inpatient, outpatient, or carrier claim diagnosis of depression within one year
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after diagnosis of HNC. Individuals whose reporting source indicated they were diagnosed with
cancer at the time of death or autopsy were excluded from all analyses for the present study.
Five-year survival of all patients was examined, with censoring time being December
2010 (the end of the study period). The survival of patients was identified using the number of
years and months of survival provided in SEER data. For this variable, survival time was
calculated using the date of diagnosis and either the date of death, date last known to be alive, or
December of 2010 for the study data. Survival outcomes of interest included all-cause and
cancer-specific death based on SEER data reporting. For all-cause mortality, vital status at the
end of the study period (December 2010) was used. For cancer specific survival, deaths attributed
to HNC were treated as events and deaths from other causes were treated as censored observation
(78).

Statistical analysis. Kaplan-Meier curves were used to examine basic survival estimates
by depression status of patients. Cox regression models were used to control for potential
confounding variables. Covariates included in the models were determined using forward
selection and clinical importance. Candidate covariates included sociodemographic information
taken from SEER data, with education and income based on census tract. Because survival
outcomes may differ by treatment received, radiation as part of the initial course of treatment
(dichotomous variable) was included as a potential covariate. Additionally, because survival may
differ by time of onset of depression, depression based on time of diagnosis was examined as a
potential covariate in the model. Medical comorbidity was measured using an adaptation of the
Charlson Comorbidity Index (CCI) developed for Medicare data (159-161). All analyses were
performed using SAS 9.4, with the default method used to handle ties within the data (Breslow
method). For the multivariable models, time-dependent variables were entered into the models to
test the proportional hazards assumption of each variable. Forward selection was used to fit the
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models, with significant time-dependent variables left in the model as the interaction of each of
these time-dependent variables with survival time.

Results

Bivariate analysis. Based on the inclusion and exclusion criteria listed above, there were
3,533 individuals eligible for inclusion in the analyses. From these, an additional 67 individuals
were excluded for being diagnosed with cancer at the time of death or autopsy, leaving a total of
3,466 individuals in the study sample (Appendix A). Table 1 shows the demographic and clinical
characteristics of the study sample by depression status over the course of cancer. Of the study
sample, 361 individuals (10.4%) had a diagnosis of depression prior to HNC diagnosis, an
additional 281 individuals (8.1%) developed depression after cancer diagnosis, and 2,824
individuals (81.5%) were not diagnosed with depression at any point during the study period. As
can be seen from Table 1, there were significant differences between the groups in terms of
survival for both cancer–specific and all-cause mortality. For cancer-specific deaths, there were
over 35% more deaths from cancer in those who were diagnosed with depression prior to cancer
compared to those who were never diagnosed with depression (48.8% vs. 36.0%, respectively).
Similarly, there were over 41% more deaths from cancer in those who were diagnosed with
depression after their cancer diagnosis compared to those where never diagnosed with depression
(50.9% vs. 36.0%, respectively). Other significant differences between groups included age,
gender, ethnicity, marital status, stage, medical comorbidity, and receipt of radiation. When
looking at all-cause mortality, there were over 35% more deaths in the group diagnosed with
depression prior to cancer diagnosis compared to those who were never diagnosed with
depression (77.6% vs. 57.4%, respectively). Similarly, when looking at those who developed
depression after cancer diagnosis compared to those who were never diagnosed with depression,
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there were nearly 30% more deaths in the group that developed depression after cancer (74.4%
compared to 57.4%, respectively).
The Kaplan-Meier survival curves for cancer-specific death by depression status showed
those without a diagnosis of depression during the specific time period had better survival
compared to those who received a depression diagnosis, either before or after cancer (Log Rank
chi square =63.03, p=<0.0001). Those who received a diagnosis of depression prior to cancer had
a median survival time of 37 months, compared to 29 months for those who received a diagnosis
of depression after cancer diagnosis. The median survival time could not be computed for those
who received no diagnosis of depression as median survival exceeded the 60 month follow-up
period.
Similarly, for all-cause mortality, individuals without a depression diagnosis had better
survival outcomes compared to those who received a depression diagnosis, either before or after
cancer diagnosis (Log Rank chi square = 99.56, p=<0.0001). Those who received a diagnosis of
depression prior to cancer had a median survival time of 17 months, compared to 18 months for
those who received a diagnosis of depression after cancer diagnosis, and 46 months for those who
received no diagnosis of depression.

Multivariable Analysis. Table 2 shows the multivariable analysis results for the outcome
of cancer-specific death. As can be seen from the table, depression diagnosis was significantly
associated with cancer death in the multivariable model after controlling for all other covariates.
Compared to those who received no depression diagnosis, those who were diagnosed with
depression prior to cancer diagnosis had nearly 1.5 times the hazard of cancer death, while those
who were diagnosed with depression after cancer diagnosis had nearly 1.4 times the hazard of
cancer death. Other significant variables associated with cancer death included age, marital status,
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income, specific cancer site, stage at diagnosis, medical comorbidity, receipt of radiation and the
interaction of receipt of radiation over time.
The multivariable results for all-cause mortality are show in Table 3. Again, depression
was found to be significantly associated with the outcome after controlling for demographic and
clinical variables. Those who were diagnosed with depression prior to cancer diagnosis had 1.55
times the hazard of any death compared to those who received no depression diagnosis. Similarly,
those who received a diagnosis of depression after had 1.40 times the hazard of any death. Other
variables that were found to be significantly associated with all-cause mortality included age,
marital status, gender, race, income, specific cancer site, stage at diagnosis, medical comorbidity,
receipt of radiation, and the interaction of time with age, marital status, race, and receipt of
radiation.

Discussion
This study showed that HNC patients with a diagnosis of depression had significantly
greater risk for death from cancer and death from any cause. Even after controlling for potential
confounding variables, including stage of cancer at the time of diagnosis, individuals with a
diagnosis of depression had 38% and 49% greater hazard of cancer-specific mortality and 40%
and 55% greater hazard of all-cause mortality compared to those patients who never received a
depression diagnosis.
The results of our study support those of several previous studies which have examined
the association of depression on the survival of various types of cancer. Patients with cancers
such as those of the breast (80; 168; 172), prostate (81), and lung (173) who also struggle with
depression or depressive symptoms have been shown to have decreased survival compared to
their non-depressed counterparts. Several previous studies of smaller scale have also examined
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the association of depression on survival of individuals with cancers of the head and neck. In a
prospective study of 241 patients, Kim et al. found that HNC patients with pre-treatment
depression had decreased 3-year survival compared to their non-depressed counterparts (87). In a
clinical trial of prophylactic depression treatment of HNC patients, Lazure et al. found that
patients with depression had significantly greater mortality and disease recurrence compared to
those who were not depressed (75). Similarly, Shinn et al. found that, of 130 patients with
oropharynx cancer, self-reported depression was associated with a 3.6 greater hazard of death and
3.8 greater hazard of disease recurrence (167). Further, Kam et al. found that individuals with
HNC have 3 times greater incidence of suicide compared the general population in the United
States (72). They also found an association with radiation and depression which is again
confirmed in this study. Previous work by our group has also shown a higher risk of emergent
depression in patients that undergo radiation as part of their primary treatment for HNC (71).
Together with the present study, these studies underline the importance of patient psychological
health during the diagnostic and treatment process of HNC, as well as the need for the recognition
of past and current depressive symptoms by clinicians especially in those undergoing radiation as
part of their treatment.
The present study adds to the existing literature of the effects of depression on survival of
HNC in several ways. By utilizing a large, population-based sample, this study provides
information on the relationship between depression and survival which may be more
representative of the elderly HNC population than previous smaller-scale studies. Further, by
examining the diagnoses of depression both before and after cancer diagnosis, the results offer a
unique look at the influence that pre-existing depression may have on cancer outcomes, in
addition to incident depression after cancer diagnosis. Based on our findings, future studies
examining outcomes of HNC and other cancer patients should consider both current and
historical psychological health of patients.
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In terms of study limitations, we identified depression based on ICD-9-CM codes,
thereby limiting our findings to only those individuals with diagnosed depression. Because of
this, we are not able to capture the influence that sub-clinical or underdiagnosed depression may
have on survival outcomes of this population. Additionally, our study did not include information
on depression treatments received, which may have additional influence on survival. Further,
Medicare only includes data in individual 65 and older, and the present study included only
individuals 67 years of age and older in order to be able to examine depression diagnosis prior to
cancer. The age limitation of both the data and our selection criteria do not allow for the
examination of the effect of depression on younger patients. Another limitation of the present
study is the lack of information on human papillomavirus (HPV) status of the study subjects.
Previous research on oropharyngeal cancer has shown that HPV-positive patients may have better
survival than those without the virus (174). Unfortunately, because there is no information on
HPV status within SEER-Medicare files, we were unable to examine or control for this
relationship in our study. However, this may only affect survival of patients with specific forms
of HNC, and the current study can still be used to estimate the effect of depression on survival of
HNCs as a group. Strengths of the present study include a large sample size as well as
diagnostically confirmed cancer and depression in the selected sample.

Conclusion
In our study, depression diagnosis was associated with decreased survival in HNC
patients. These results emphasize the need for strategies designed to prevent depression, early
identification and treatment of depression in HNC patients, as well as the establishment of
policies to routinely screen these patients throughout the cancer treatment process. Identifying
and treating depression in these patients may not only help to improve quality of life during
cancer treatment and recovery, but may also help to improve survival in these patients.
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Table 1. Profile of the study sample by depression status

Variable
Age
67-69
70-74
75-79
80-84
85+
Gender
Male
Female
Ethnicity
Non-Hispanic white
Other
% With 4 year college degree
0-33%
34+%
Missing
Marital status
Married/Living as Married
Separated/Divorced
Single
Widowed
Unknown
Median Income Census Tract
< $35, 000 or Missing
$35, 000- $44,999
$45, 000- $59,999
$60, 000+
Cancer Site
Lip
Oral Cavity
Oropharynx
Nasopharynx/Hypopharynx
Larynx
SEER Region
Pacific/West
Northeast
Midwest
South
Stage
Unstaged
InSitu/Localized
Regional
Distant
Charlson Comorbidity
0
1+
Radiation Received
No
Yes
Any Death
No
Yes
Cancer Death
No
Yes

Pre-Cancer
Depression (N=361)
N %

Post-Cancer
Depression
(N=281)
N %

No Depression
(N=2,824)
N %

p-value
0.0061

60
106
73
68
54

16.6%
29.4%
20.2%
18.8%
15.0%

52
99
52
52
26

18.5%
35.2%
18.5%
18.5%
9.3%

615
788
635
418
368

21.8%
27.9%
22.5%
14.8%
13.0%

196
165

54.3%
45.7%

167
114

59.4%
40.6%

1931
893

68.4%
31.6%

324
37

89.8%
10.2%

240
41

85.4%
14.6%

2353
471

83.3%
16.7%

245
90
26

67.9%
24.9%
7.2%

197
72
12

70.1%
25.6%
4.3%

2025
644
155

71.7%
22.8%
5.5%

148
39
31
124
19

41.0%
10.8%
8.6%
34.3%
5.3%

131
23
29
83
15

46.6%
8.2%
10.3%
29.5%
5.3%

1499
249
239
671
166

53.1%
8.8%
8.5%
23.8%
5.9%

118
86
75
82

32.7%
23.8%
20.8%
22.7%

84
63
69
65

29.9%
22.4%
24.6%
23.1%

897
649
633
645

31.8%
23.0%
22.4%
22.8%

26
103
96
35
101

7.2%
28.5%
26.6%
9.7%
28.0%

18
66
80
24
93

6.4%
23.5%
28.5%
8.5%
33.1%

228
654
736
255
951

8.1%
23.2%
26.1%
9.0%
33.7%

155
57
47
102

42.9%
15.8%
13.0%
28.3%

98
73
40
70

34.9%
26.0%
14.2%
24.9%

1085
558
391
790

38.4%
19.8%
13.8%
28.0%

37
149
107
68

10.2%
41.3%
29.6%
18.8%

27
98
102
54

9.6%
34.9%
36.3%
19.2%

285
1278
881
380

10.1%
45.3%
31.2%
13.5%

290
71

80.3%
19.7%

263
18

93.6%
6.4%

2650
174

93.8%
6.2%

186
175

51.5%
48.5%

85
196

30.2%
69.8%

1261
1563

44.7%
55.3%

81
280

22.4%
77.6%

72
209

25.6%
74.4%

1204
1620

42.6%
57.4%

185
176

51.2%
48.8%

138
143

49.1%
50.9%

1808
1016

64.0%
36.0%

<0.0001

0.0059

0.3212

0.0002

0.9547

0.3433

0.0572

0.0021

<0.0001

<0.0001

<0.0001

<0.0001
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Table 2. Multivariable results for cancer-specific mortality
Variable
Depression Status
No Depression Diagnosis
Pre-HNC Depression
Post-HNC Depression
Age
67-69
70-74
75-79
80-84
85+
Marital Status
Married/Living as Married
Single
Widowed
Divorced/ Separated
Unknown
Median Income Census Tract
< $35, 000 or Missing
$35, 000- $44,999
$45, 000- $59,999
$60, 000+
Cancer Site
Lip
Larynx
Nasopharynx/Hypopharynx
Oral Cavity
Oropharynx
Stage
In Situ/Localized
Regional
Distant
Unstaged
Charlson Comorbidity
0
1+
Radiation Received
No
Yes
Radiation*TIME

HR

95% CI

REF
1.49
1.38

1.27
1.16

1.76
1.65

REF
1.15
1.55
1.83
2.32

0.98
1.30
1.52
1.90

1.36
1.84
2.20
2.82

REF
1.30
1.41
1.44
1.06

1.07
1.24
1.19
0.80

1.57
1.06
1.74
1.39

REF
0.77
0.72
0.71

0.66
0.61
0.61

0.89
0.84
0.82

REF
3.54
5.52
3.47
3.71

2.38
3.64
2.34
2.49

5.24
8.35
5.15
5.52

REF
3.30
4.93
2.68

2.83
4.17
2.20

3.86
5.83
3.28

REF
1.47

1.21

1.80

REF
0.48
1.03

0.41
1.02

0.57
1.04

p-value

Type 3
p-value
<0.001

<0.001
<0.001
<0.001
0.098
<0.001
<0.001
<0.001
<0.001
0.008
<0.001
<0.001
0.702
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

<0.001
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Table 3. Multivariable results for all-cause mortality
Variable

HR

Depression Status
No Depression Diagnosis
Pre-HNC Depression
Post-HNC Depression
Age
67-69
70-74
75-79
80-84
85+
Age*TIME

95% CI

REF
1.55
1.40

1.36
1.21

1.76
1.62

REF
1.15
1.47
1.67
2.40
1.00

1.00
1.26
1.39
1.96
1.00

1.33
1.73
2.02
2.95
1.01

REF
1.38
1.62
1.52
1.31
1.00

1.16
1.40
1.29
1.03
1.00

1.63
1.88
1.78
1.67
1.00

Male
Female

REF
0.84

0.76

0.93

Non-Hispanic white
Other

REF
1.28
0.99

1.09
0.99

1.51
1.00

REF
0.82
0.75
0.73

0.73
0.66
0.64

0.92
0.84
0.82

REF
1.66
2.46
1.61
1.74

1.35
1.93
1.30
1.40

2.05
3.13
1.99
2.16

REF
2.34
3.27
2.08

2.08
2.86
1.79

2.63
3.73
2.43

REF
1.86

1.61

2.15

REF
1.64
1.01

1.44
1.01

1.88
1.02

Marital Status
Married/Living as Married
Single
Widowed
Divorced/ Separated
Unknown
Marital*TIME

p-value

Type 3
p-value
<0.001

<0.001
<0.001
<0.001
0.052
<0.001
<0.001
<0.001
<0.001

<0.001
<0.001

<0.001
<0.001
<0.001
0.028
0.015

0.015
<0.001

Gender
<0.001

0.003

Race

Race*TIME
Median Income Census Tract
< $35, 000 or Missing
$35, 000- $44,999
$45, 000- $59,999
$60, 000+
Cancer Site
Lip
Larynx
Nasopharynx/Hypopharynx
Oral Cavity
Oropharynx
Stage
In Situ/Localized
Regional
Distant
Unstaged
Charlson Comorbidity
0
1+
Radiation Received
No
Yes
Radiation*TIME

0.003
<0.001

<0.001
<0.001

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

<0.001
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CHAPTER V
RADIATION SIDE-EFFECTS AND DEPRESSION IN HEAD AND NECK CANCER
PATIENTS

Abstract

Background. The influence of radiation side-effects on psychological distress of head
and neck cancer (HNC) patients is not well understood. The objective of this study was to
examine the association between radiation treatment side-effects and depression outcomes in
HNC patients.

Methods. SEER-Medicare data was examined for 1,759 HNC patients who received
radiation as part of their initial course of treatment. Radiation side-effects in Medicare data were
identified and examined in their association with one year post-cancer depression diagnosis.

Results. Nearly 85% of those in the depressed group were diagnosed with at least one
radiation side-effect, compared to 59% of the non-depressed group. A diagnosis of at least one
radiation side-effect was associated with 3.70 (95% CI= 2.47, 5.55) times the odds of being
diagnosed with depression.

Conclusions. It appears that potential side-effects of radiation are associated with the
emotional well-being of HNC patients during the first year following cancer diagnosis.
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Introduction
Radiation therapy is a well-established treatment for head and neck cancers (HNC), with
half or more of all HNC patients receiving some form of radiation as part of their cancer
treatment (34; 175). Unfortunately, this treatment has also been associated with a number of sideeffects and toxicities which can be detrimental to HNC patients (55; 62; 176). Common sideeffects of radiation treatment in HNC patients include xerostomia (dry mouth) and other salivary
problems, oral health issues, malnutrition, and extreme fatigue (63-68). These side-effects can not
only cause physical impairment in HNC patients, they may also affect the emotional well-being
of these individuals (62; 176).
HNC patients in particular may be at risk for depression development due to the physical
disfigurement and functional impairment that accompany the treatment of these cancers (53; 54).
Previous literature has shown that individuals who receive radiation treatment have poorer quality
of life and may have increased mental health issues or mental distress (67; 71). Further, patients
who received radiation therapy have been shown to have an increased risk of depression
development as treatment persists (62). While this treatment modality may be beneficial for
survival, there is a dearth of research examining the influence that radiation side-effects may have
on the psychological health of this group of patients already at risk for depression.
Though previous studies have suggested that radiation side-effects may influence
psychological health (62; 102; 134; 176), few studies that have specifically examined the
influence of treatment side-effects on depression development in HNC patients, even though the
risk in this population may particularly high. Because of the frequency of radiation treatment and
increased risk for psychological illness or distress in this population, and the treatment options
available for depression, there is a clear need to explore the associations between the side-effect
of this treatment and depression diagnosis in HNC patients. The objective of the present study
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was to examine the association between radiation treatment side-effects and depression outcomes
in HNC patients.

Methods
The methods for sample selection have been previously reported (177). Briefly, utilizing
Surveillance Epidemiology and End Results (SEER)-Medicare linked data from 2002-2010, we
identified all individuals diagnosed with HNC from 2004-2005. From this group, diagnosis of
depression was identified using ICD-9-CM codes from Medicare inpatient, outpatient, or carrier
claim claims data. Individuals whose reporting source indicated they were first diagnosed with
cancer at the time of death or autopsy were excluded from all analysis. For the present study, we
excluded individuals who had a diagnosis of depression during the two years prior to their cancer
diagnosis in order to be able to capture incident depression cases. The study sample was also
limited to those individuals who received radiation as part of their initial course of treatment,
either alone or in addition to other treatments.
ICD-9-CM codes for potential side-effects of radiation treatment were identified from
previous literature and clinical judgment. Side-effect diagnostic codes included: Xerostomia
(527.7); Dysphagia (787.2, 787.21-787.24, 787.29); Aspiration (507.0, 508.9); Malnutrition (260,
261, 262, 263, 263.1, 263.8-263.9, 799.4); Fatigue or Malaise (780.7, 780.79); Radiation sickness
(366.46, 692.82, 990, 909.2); Speech disturbances (784.59, V40.1, V57.3); and Dental caries
(521, 521.01-521.04, 521.06-521.09; 525.13; 526.89). Patients had to have at least one inpatient,
outpatient, or carrier claim diagnosis of a given side-effect within one year of cancer diagnosis to
be included within a given side-effect group.
Bivariate analyses were carried out to examine basic differences in side-effects between
those with and without a depression diagnosis. Multivariable logistic regression was used to
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examine the association between side-effects and depression outcomes while controlling for
potential confounding factors. All two-way interactions were investigated between the following
variables: race, income, age, sex, cancer stage and site. Forward selection was used to fit the
multivariable logistic regression model with the p-value<0.15 for entry and data were analyzed
using SAS version 9.4.

Results

Bivariate Analysis. The final sample included 1,759 patients who were diagnosed with
HNC between 2004-2005 and met all inclusion criteria for the study. Table 1 shows the
demographic and clinical characteristics of the study sample by depression status. The only
significant differences in group characteristics were gender and marital status. A greater
proportion of those in the non-depressed group were male (72.9% versus 58.7%), and a greater
proportion of those in the non-depressed group were married or living as married at the time of
diagnoses when compared to the depressed group (57.6% versus 49.5%, respectively).
Table 2 shows the radiation side-effects in the study sample by depression status. Overall,
there were significant differences in diagnosed side-effects by depression status for all sideeffects examined (dysphagia, aspiration, malnutrition, and fatigue or malaise), other than
xerostomia. Other than the xerostomia, over three quarters of the depressed group had a diagnosis
of each side-effect, compared to less than half in of the non-depressed group. Though the
difference was not statistically significant, a greater proportion of the depressed group received a
diagnosis of xerostomia compared to the non-depressed group (10.2% versus 6.8%, respectively).
When looking at all side-effects combined, nearly 85% of the depressed group had at least one
side-effect diagnosis in the year following cancer diagnosis, compared to only 59% in the nondepressed group.
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Multivariable Analysis. Table 3 shows the multivariable results of the factors associated
with depression diagnosis in HNC patients. As in the bivariate analysis, females had greater odds
of receiving a diagnosis of depression following HNC when compared to males (OR= 1.78; 95%
CI= 1.30, 2.44). As can be seen from the table, gender and side-effect diagnosis were
significantly associated with depression diagnosis. Having diagnosis of at least one radiation
side-effect was associated with 3.70 (95% CI= 2.47, 5.55) times the odds of being diagnosed with
depression compared to those with no radiation side-effect diagnoses.

Discussion
In this study, over half of the patient sample received a diagnosis of dysphagia,
aspiration, malnutrition, or fatigue or malaise during the year following cancer diagnosis. Further,
nearly 62% of the HNC patient sample had at least one potential radiation side-effect diagnosis
within the first year of cancer diagnosis. Specific to the influence of side-effects on psychological
health of patients, nearly 85% of those with a depression diagnosis were also diagnosed with at
least one radiation side-effect, compared to only 59% of the non-depressed population. Even after
controlling for age, gender and ethnicity, HNC patients who had received a diagnosis of at least
one of the proposed radiation side-effects had nearly four times the odds of depression compared
to those with no side-effect diagnoses. Based on the results of this study, it appears that potential
side-effects of radiation are associated with the emotional well-being of HNC patients during the
first year following cancer diagnosis.
The results of the present study add to and are supported by the existing literature
examining the association of radiation and depression in the HNC population. Chen at al. (2010)
found that symptom severity related to oral cancer was significantly associated with both
depression and radiation dose in a sample of 76 oral cavity cancer patients receiving radiation
(134). Additionally, Nguyen et al. (2010) found that severity of dysphagia was associated with
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risk of depression in HNC patients (178). Previous work by Kelly at al. (2007), Rose at al. (2001),
and Chen et al. (2009) found that patients receiving radiation treatment had increased level of
depression as their radiation treatment progressed (62; 102; 176). Comparing radiation treatment
with other cancer treatments, in a clinical trial of prophylactic antidepressant use in HNC patients,
Lydiatt et al. (2013) found that individuals who received radiation as part of their initial course of
treatment had greater mean depression rates compared to those who only received surgery (71).
Additionally, Kam et al. (2015) found that HNC patients treated with radiation only or radiation
with surgery had greater incidence of suicide compared to those treated with only surgery (72).
There are several limitations that should be taken into account when interpreting the
results of this study. First, we identified depression in this patient population by diagnostic codes
from Medicare data. Because of this, HNC patients with subclinical or undiagnosed depression
were not included in the depression group in this study. Further, we eliminated those with preexisting depression from inclusion in the study, a group which may be more likely to develop
depression after cancer diagnosis. In spite of this, the significant results of this study are still
relevant, since any subsequent misclassification would result in an underestimate of the influence
that radiation side-effects have on depression diagnosis in the HNC population. Another
limitation of this study is the lack of ability to identify a temporal relationship between depression
development and radiation side-effects. Receipt of a diagnosis of both depression or side-effects
of radiation would require a scheduled appoint with a healthcare provider and diagnostic date
would, therefore, depend on appointment availability. Because of this, the analysis of this study
only examined the association between side-effect diagnosis and depression diagnosis with the
year following HNC diagnosis, without concern for which was diagnosed first. Further, this study
focused on patients who received radiation with or without other treatments. It is possible that
additional treatments, such as surgery or chemotherapy, may be indicative of severity of cancer or
of other side-effects, such as physical disfigurement, and therefore be associated with depression
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development. However, given the nature of the data, additional treatments would only be proxies
for factors, and therefore were not included in the analyses. Finally, diagnostic codes for the sideeffects of radiation were taken from previous literature and identified through medical records. It
is possible that these side-effect diagnoses were unrelated to radiation treatments received by
patients. However, the side-effects diagnostic codes used in this study were limited to those
reported more commonly in the literature or that are specific to radiation treatments, giving
credence to the results.
The study has several implications on both clinical practice and future research. First, for
patients who will be undergoing radiation treatment, prevention measures should be taken prior to
treatment initiation in order to help reduce side-effect symptomology. As outlined in a review by
Andrews and Griffiths (2001), there are a number of prevention and management efforts that can
be made in order to reduce dental complications associated with radiation therapy including pretreatment assessments and potential extractions. Use of agents such as oral lubricants or
fluoridation methods in irradiated patients may help reduce oral and dental complications (179).
Further, monitoring of side-effects and treatment of side-effects in patients may be necessary in
order to improve psychological health and quality of the in these patients. Follow up support
during treatment, such as nutritional counselling, may be beneficial in helping to each side-effects
of radiation. In practice, healthcare providers should monitor and screen patients undergoing
radiation treatment for depression on a regular basis, especially those who develop treatment sideeffects. In terms of implications on research, future studies examining psychological well-being
in the HNC population should include information about treatments received and the side-effects
associated with these treatments. Additionally, future prospective studies should also include
information on physical disfigurement and functional impairment that may be caused by
additional treatment received, such as surgery. Finally, the present study was unable to show
temporality in the relationship between side-effect diagnoses and depression, and therefore unable

61
to determine a causal relationship. Future research should try to identify whether side-effects
precede depression, or whether depression precedes side-effects in order to potentially improve
depression screening or side-effect outcomes in the HNC population.

Conclusions
The results of this study suggest that not only are side-effects of radiation common in
HNC patients receiving radiation therapy, but that these side-effects may be associated with
depression development in this patient population. Care needs to be taken in order to mitigate
radiation side-effects and to screen for depression in HNC patients undergoing radiation therapy,
especially those at increased risk for depression development.
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Table 1. Profile of the study sample by depression status
No Depression
N=1563
N
%
Age
67-69
399
25.5%
70-74
461
29.5%
75-79
352
22.5%
80-84
209
13.4%
85+
142
9.1%

Depression
N=196
N

p-value
%
0.053

43
71
33
35
14

21.9%
36.2%
16.8%
17.9%
7.1%

Gender
Male
Female

1139
424

72.9%
27.1%

115
81

58.7%
41.3%

Ethnicity
Non-Hispanic white
Other

1266
297

81.0%
19.0%

167
29

85.2%
14.8%

662
901

42.4%
57.6%

99
97

50.5%
49.5%

Marital vs. Not
Not Married/Living as Married
Married/Living as Married
Median Income Census Tract
< $35, 000 or Missing
$35, 000- $44,999
$45, 000- $59,999
$60, 000+
Cancer Site
Oral Cavity and lip
Oropharynx
Nasopharynx/Hypopharynx
Larynx
SEER Region
Pacific/West
Northeast
Midwest
South
Charlson Comorbidity
0
1+
Stage
Missing/Unstaged
In Situ/Localized
Regional
Distant

<0.001

0.153

0.030

0.874
502
357
345
359

32.1%
22.8%
22.1%
23.0%

63
43
48
42

32.1%
21.9%
24.5%
21.4%
0.536

263
466
175
659

16.8%
29.8%
11.2%
42.2%

38
64
21
73

19.4%
32.7%
10.7%
37.2%
0.123

601
329
199
434

38.5%
21.0%
12.7%
27.8%

67
53
30
46

34.2%
27.0%
15.3%
23.5%
0.952

1469
94

94.0%
6.0%

184
12

93.9%
6.1%

103
576
630
254

6.6%
36.9%
40.3%
16.3%

16
55
86
39

8.2%
28.1%
43.9%
19.9%

0.097
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Table 2. Potential radiation side-effects in the study sample by depression status
No Depression
Depression
N=1563
N=196
N
%
N
%
Side-Effects
Xerostomia
No
1457
93.2%
176
89.8%
Yes
106
6.8%
20
10.2%
Dysphagia
No
Yes

799
764

51.1%
48.9%

41
155

20.9%
79.1%

Aspiration
No
Yes

830
733

53.1%
46.9%

44
152

22.4%
77.6%

Dental Caries
No
Yes

857
706

54.8%
45.2%

47
149

24.0%
76.0%

p-value

0.799

<0.001

<0.001

<0.001

Malnutrition
No
Yes

<0.001
792
771

50.7%
49.3%

40
156

20.4%
79.6%

Fatigue or Malaise
No
Yes

789
774

50.5%
49.5%

41
155

20.9%
79.1%

Speech Disturbances
No
Yes

851
712

54.4%
45.6%

46
150

23.5%
76.5%

<0.001

<0.001

Radiation Sickness/Dermatitis
No
Yes

<0.001
847
716

54.2%
45.8%

45
151

23.0%
77.0%

Osteoradionecrosis of Jaw
No
Yes

858
705

54.9%
45.1%

47
149

24.0%
76.0%

Any Side-Effect
No
Yes

642
921

41.1%
58.9%

30
166

15.3%
84.7%

<0.001

<0.001
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Table 3. Multivariable analysis of depression diagnosis in HNC patients
OR
95% CI
Age
Ages 67-69
REF
Ages 70-74
1.29
0.86
1.94
Ages 75-79
0.78
0.48
1.27
Ages 80-84
1.37
0.84
2.24
Ages 85+
0.78
0.41
1.50

p-value

0.077
0.118
0.077
0.277

Gender
Male
Female

REF
1.78

1.30

2.44

<0.001

Ethnicity
Non-Hispanic White
Other

REF
0.70

0.46

1.07

0.097

Any Side-Effect
No
Yes

REF
3.70

2.47

5.55

<0.001
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CHAPTER VI
DISCUSSION AND CONCLUSIONS

Summary of Current Research
HNCs are a group of cancers that, although somewhat rare in the United States, appear to
be highly associated with the psychological health of patients. Individuals with HNC have to deal
with not only the physical effects of the disease and its treatments, but social, financial, and
emotional effects of the disease as well (53; 55). Because of the unique ways HNC can affect
human life, this group of patients may be at increased risk for depression development when
compared to other cancer sites (49; 51). While previous studies have been conducted to examine
the psychological effects of HNC more closely, there are still significant gaps in the literature
regarding the understanding how often HNC patients are afflicted with depression, as well as the
consequences of this on outcomes. This dissertation sought to help narrow some of the existing
gaps in the literature and to bring attention to the salient biopsychosocial factors that affect
patients during HNC development, diagnosis, and treatment. .
The SEER-Medicare linked database provided an opportunity to explore the relationship
between depression and HNC in a national, representative sample of older adults diagnosed with
HNC. This linked databased allowed us to utilize a standard method of identifying both HNC and
depression diagnoses through diagnostic codes in exiting medical record data. Further, a
secondary analysis of SEER-Medicare data afforded us the ability to study a large number of
patients with HNC, which is a relatively rare disease. This data also allowed us to include several
potential confounding variables that have been identified in the existing literature when
examining the relationship between cancer diagnosis and depression.
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Chapter 2 of this dissertation utilized existing literature in order to better understand the
potential ways in which depression may develop in patients with cancers of the head and neck.
Previous studies have identified both individual and contextual-level factors that can influence the
development of depression after cancer diagnosis. Further, based on our review and synthesis,
there are also individual and contextual factors that can influence depression diagnosis before
cancer, which may leave individuals at increased risk for HNC. From the resulting conceptual
model, it can be seen that there are a number of factors that can influence depression in HNC
patients at all stages. However, most previous literature was based on smaller-scale studies, which
may not have been representative of the HNC population as a whole.
Utilizing SEER-Medicare data, Chapter 3 of this dissertation examined the frequency at
which individuals with HNC are diagnosed with depression. This data allowed the examination of
over 3,500 individuals from more than 20 locations in the U.S. Based on the study results, some
form of depression is diagnosed in nearly 19% of HNC patients. Of this group, nearly 11% are
diagnosed with depression before HNC and an additional 9% develop depression within the first
year of cancer diagnosis. Additionally, the multivariable analyses showed that those with
depression had greater odds of being diagnosed with distant stage HNC and those who developed
depression were diagnosed with later stage of cancer at the time of diagnosis. Chapter 4 further
studied one segment of the sample from Chapter 3 and examined the potential effect that
depression diagnosis may have on the survival of HNC patients. The results of Chapter 4 clearly
showed that individuals diagnosed with depression had significantly poorer survival when
compared to individuals who received no diagnosis of depression during the study period.
The final study of this dissertation focused on a sub-group of the patient sample from
Chapter 4. In this chapter, the potential side-effects of radiation in HNC patients were examined
in relation to depression development within the first year of cancer diagnosis among those
without pre-existing depression. The results of the Chapter 5 study indicate that HNC patients
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experiencing side-effects of their radiation treatments may be a greater risk for depression
diagnosis than those who do not experience side-effects. Together, the studies from these chapters
offer new insight into the relationship between depression and HNC.

Implications of Current Research
The findings of this dissertation have extensive clinical implications. The results of all
studies from this dissertation emphasize the notion that HNC is both a physically and emotionally
traumatic diagnosis, and that healthcare workers, family members, and patients need to be
watchful of the potential signs of depression. Recent guideline adaptations released by the
American Society of Clinical Oncology and the National Comprehensive Cancer Network
recommend that all patients who receive a diagnosis of cancer be screened for depression and
anxiety at their first visit, and at other times during the course of cancer that could result in
changes in emotional well-being, such as at the beginning of treatment (180; 181). Also
applicable to the current study population, the US Preventive Services Task Force recommends
regular depression screening for older adults, utilizing tools such as the Patient Health
Questionnaire (PHQ) (182).
Along with screening for depression, Stout et al. discussed the idea of making emotional
well-being a part of the patient’s model of care and helping them think of emotional health as a
targeted outcome of their cancer recovery (183). The authors also suggested that educating
patients about their disease and treatments may be beneficial in reducing unnecessary stress and
including family and friends in some of the skill building strategies for coping may give added
support (183). The results of this dissertation show just how common diagnosable depression may
be in this cancer population. Identifying those who may be at risk for, or dealing with, depression
is the first step in helping these individual improve their psychological health.
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In addition to identifying existing depression in the HNC and other cancer population,
emphasis should also be placed on preventing depression in those individuals without depressive
symptoms. As has been discussed in this dissertation, depression can afflict patients throughout
the diagnosis and treatment of cancer. Lydiatt et al. (2013) found that prophylactic use of
antidepressants can help prevent depression development in HNC patients (71). Healthcare
workers and patients should consider preventative measures, such as psycho pharmaceutical or
psychotherapeutic interventions for the prevention of depression, both during and after cancer.
In addition to prevention and early detection of depression in newly diagnosed cancer
patients, the results of Chapter 3 also support the notion of HNC screening in those with
depression. The results of the study indicated that individuals with preexisting depression may be
at increased risk for later stage HNC at diagnosis. It is possible that these individuals have higher
risk factors and lower self-care and, therefore, may not seek medical attention during the early
stages of HNC. Based on these results, it may be beneficial to screen individuals who have been
diagnosed with depression for HNC, specifically if they engage in other risky behavior related to
the disease such as alcohol or tobacco use. Screening this higher risk population may help to
detect HNC at earlier stages, leading to better prognoses and less invasive or extensive treatment.
Chapter 4 of this dissertation found that survival among HNC patients with depression
was significantly worse when compared to those without depression. These results give support to
not only the notion of depression screening but also the need for depression treatment in the HNC
population. Depression treatments can include psychosocial or pharmacological treatments, and
both have shown to be effective in cancer populations (180; 184). Further, a study by Lydiatt et
al. found that prophylactic use of antidepressants may reduce depression development in the HNC
population (71). Identifying and treating HNC patients experiencing depression, or preventing
depression development, may improve survival outcomes in this patient population.
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The results of Chapter 5 of this dissertation found a significant association between
potential side-effects of radiation treatment and depression, indicating that individuals
experiencing radiation side-effects may be at greater risk of depression. While a causative
relationship cannot be assumed given the study methods, healthcare providers may consider
taking preventative measures before radiation treatment aimed at reducing the risk of side-effect
development in the HNC population. Additionally, providers should be vigilant of side-effects in
patients’ treatments with radiation, and screen these patients periodically during treatments in
order to identify and treat depression, as well as mitigate side-effect symptoms.

Suggested Future Research
The work in this dissertation adds to the existing literature on the relationship between
HNC and psychological health. However, there are still many gaps in the literature on which
future research in this area should focus. Based on the results of this dissertation, several future
directions are suggested.
The second chapter of this dissertation focused on the development of a conceptual
model for understanding the relationship between depression and HNC, which was based on
previous peer-reviewed literature. This model, which may help in guiding future research,
included individual and environmental factors that may influence this relationship between
depression and cancer in the HNC population. However, many of these same factors may apply to
other cancer sites in terms of depression diagnosis, especially for other substance abuse-related
cancers, such as lung or esophageal. To continue to understand the influence depression may have
on health throughout the life course, future research should include developing conceptual models
of the relationship between depression and cancer diagnosis, focusing on depression before and
after cancer diagnosis.
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The current research found that the prevalence of preexisting depression was relatively
high in this population, though few studies have examined the potential increased risk of HNC
based on preexisting depression. Moreover, the results of the study done in Chapter 3 showed that
individuals with preexisting depression may present with later stage of cancer at the time of
diagnosis when compared to those without depression. Future research should further examine
the relationship between preexisting depression and cancer development as a potential avenue for
prevention of HNC by depression mitigation or early detection of HNC through screening in
individuals experiencing depression. Experimental studies should focus on implementation and
evaluation of interventions concentrated on increased awareness of early signs of HNC in highrisk populations. Future longitudinal cohort studies should further examine the potential risks that
subclinical and clinical depression may have on stage of HNC diagnosis.
The results of this dissertation work showed that individuals who received a diagnosis of
depression had worse survival when compared to those who were never depressed. This may be
due to a lack of self-care and social support, or the result of an underlying biological mechanism
related to depression. Unfortunately, given our use of secondary data, we were unable to
determine the reason for this difference. Future studies should attempt to identify the reason for
this disparity in survival. Further, while depression may be present in the HNC population, and
appears to influence survival outcomes, there is minimal literature on the preferred or
recommended treatments for depression in this cancer group. Future observational or
experimental studies should aim to identify the most beneficial treatments for depression in HNC
patients. Given the influence that depression may have on survival in these patients, finding
appropriate depression treatments in the HCN population may help to improve not only quality of
life, but also survival outcomes.
Radiation side-effects in HNC patients were found to be associated with depression
development. However, given the nature of the data used, a temporal relationship between side-
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effects and depression could not be identified. Further, side-effects were based on diagnoses from
administrative data and selected based on previous literature. Therefore, these do not fully depict
the potential consequences of radiation treatments received by these patients. Future studies
should further examine the temporal relationships between radiation side-effect and depression
diagnosis in order to explain this relationship. Additionally, future observational studies should
utilize primary data collection and qualitative methods to better understand the potential effects of
radiation treatment on the physical and psychological health of HNC patients. By collecting data
prospectively, future observational studies could also identify potential implications that preexisting depression might have on patients’ treatment decisions. In addition to observational
studies, future experimental studies should try to identify prophylactic measure that can be taken
in order to ease these side-effects in the HNC population and improve patient quality of life
during and after cancer treatments, which may help to reduce the incidence of depression during
treatment.

Limitations
This dissertation is a secondary analysis of existing administrative and registry data.
There are several limitations associated with the use of secondary data for this dissertation
research. In each study conducted in this dissertation, both depression and cancer diagnoses were
identified using diagnostic codes from the data. This method of identifying depression does not
allow for a full understanding of specific criteria that were met for depression diagnosis, and also
does not give us any indication of the severity of the diagnosis. Additionally, there may be
misclassification when utilizing administrative data, specifically in the exposure groups of these
dissertation studies. Future studies should work to utilize alternative methods for identifying
subclinical and clinical depression in the HNC population.
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In addition to the limitations presented by the identification of diagnoses, the data used
for this dissertation offers minimal information on any social support or social aspects of the lives
of these individuals. Because the nature of this dissertation research focuses on the psychological
aspects of HNC, the social lives of these patients, the support they receive, and the individuals
with which they may interact can significantly influence the study design and results. Each of the
studies conducted as part of this dissertation would benefit from having additional information
about the social aspects of these patients’ lives. Future research should strive to collect more
detailed information on received and perceived social support in these patients, as well as
information on their social networks.
In addition to the lack of information on severity of depression and social aspects of
patients’ lives, there is also a dearth of information in data concerning depression treatments for
these individuals. While SEER-Medicare does offer access to Part D files, thereby giving some
information about psychopharmaceutical treatments received by these patients, these files were
not available for all years of our study and therefore could not be explored in full. Further, SEERMedicare offers minimal information on use of other psychological treatments such as behavioral
therapy. As a result, the effectiveness of treatments received by these patients could not be
examined. Future observational and experimental studies should attempt to identify treatments
received by these individuals as well as the effectiveness of these in the HNC population.

Conclusions
Based on the results of this dissertation, approximately one in five HNC patients will also
be diagnosed with depression, which can affect the quality of life and outcomes of this cancer
population. Screening for depression throughout the course of cancer, mitigation of treatment
side-effects, and identifying appropriate depression treatments are all crucial to improving the
psychological health and survival of the HNC population.
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